

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2005 HIGHEST RN 861291-85-2
DICTIONARY FILE UPDATES: 22 AUG 2005 HIGHEST RN 861291-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> E "PEG"/CN 25

E1	1	PEFURAZOATE/CN
E2	1	PEFURAZOATE-IKI 220 MIXT./CN
E3	1	--> PEG/CN
E4	1	PEG (POLYGLYCOL)/CN
E5	1	PEG 100/CN
E6	1	PEG 1000/CN
E7	1	PEG 1000 DIAMINÉ/CN
E8	1	PEG 1000 MONOSTEARATE/CN
E9	1	PEG 10000/CN
E10	1	PEG 1000MO/CN

E11 1 PEG 1000MS/CN
E12 1 PEG 100MS/CN
E13 1 PEG 11000/CN
E14 1 PEG 115/CN
E15 1 PEG 120 METHYL GLUCOSE DIOLEATE/CN
E16 1 PEG 120 METHYL GLUCOSE TRIOLEATE/CN
E17 1 PEG 12000/CN
E18 1 PEG 13000/CN
E19 1 PEG 1450/CN
E20 1 PEG 150 STEARATE/CN
E21 1 PEG 1500/CN
E22 1 PEG 1500-1,5-PENTANEDIOL-TEREPHTHALIC ACID-TRIMETHYLOLPROPANE
COPOLYMER ESTER WITH DODECENYLSUCCINIC ANHYDRIDE/CN
E23 1 PEG 1500-1,5-PENTANEDIOL-TEREPHTHALIC ACID-TRIMETHYLOLPROPANE
COPOLYMER ESTER WITH DODECENYLPHthalic ANHYDRIDE/CN
E24 1 PEG 1500-1,5-PENTANEDIOL-TEREPHTHALIC ACID-TRIMETHYLOLPROPANE
COPOLYMER ESTER WITH PHthalic ANHYDRIDE/CN
E25 1 PEG 15000/CN

=> S E3
L1 1 PEG/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 25322-68-3 REGISTRY
CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (9CI) (CA INDEX
NAME)
OTHER NAMES:
CN α , ω -Hydroxypoly(ethylene oxide)
CN α -Hydro- ω -hydroxypoly(oxy-1,2-ethanediyl)
CN α -Hydro- ω -hydroxypoly(oxyethylene)
CN 1,2-Ethanediol, homopolymer
CN 16600
CN 1660S
CN 400DAB8
CN Alkox
CN Alkox E 100
CN Alkox E 130
CN Alkox E 160
CN Alkox E 240
CN Alkox E 30
CN Alkox E 30G
CN Alkox E 45
CN Alkox E 60
CN Alkox E 75
CN Alkox R 100
CN Alkox R 1000
CN Alkox R 15
CN Alkox R 150
CN Alkox R 400
CN Alkox SR
CN Alkox SW
CN Antarox E 4000
CN Aquacide III
CN Aquaffin
CN Badimol
CN BDH 301
CN Bradsyn PEG
CN Breox 2000
CN Breox 20M
CN Breox 4000
CN Breox 550

CN Breox PEG 300
CN CAFO 154
CN Carbowax
CN Carbowax 100
CN Carbowax 1000
CN Carbowax 1350
CN Carbowax 14000
CN Carbowax 1450
CN Carbowax 1500
CN Carbowax 1540
CN Carbowax 20
CN Carbowax 200
CN Carbowax 20000
CN Carbowax 25000
CN Carbowax 300
CN Carbowax 3350
CN PEG

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

AR 9002-90-8

DR 615575-04-7, 12676-74-3, 12770-93-3, 9081-95-2, 9085-02-3, 9085-03-4,
174460-08-3, 174460-09-4, 54510-95-1, 125223-68-9, 54847-64-2, 59763-40-5,
64441-68-5, 64640-28-4, 133573-31-6, 25104-58-9, 25609-81-8, 134919-43-0,
101677-86-5, 99264-61-6, 106186-24-7; 112895-21-3, 114323-93-2,
50809-04-6, 50809-59-1, 119219-06-6, 60894-12-4, 61840-14-0, 37361-15-2,
112384-37-9, 67411-64-7, 70926-57-7, 75285-02-8, 75285-03-9, 77986-38-0,
150872-82-5, 154394-38-4, 79964-26-4, 80341-53-3, 85399-22-0, 85945-29-5,
90597-70-9, 88077-80-9, 88747-22-2, 34802-42-1, 107502-63-6, 107529-96-4,
116549-90-7, 156948-19-5, 169046-53-1, 188364-77-4, 188924-03-0,
189154-62-9, 191743-71-2, 196696-84-1, 201163-43-1, 206357-86-0,
221638-71-7, 225502-44-3, 270910-26-4, 307928-07-0, 356055-70-4,
391229-98-4

MF (C2 H4 O)n H2 O

CI PMS, COM

PCT Polyether

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHM, CSNB, DDFU, DETHERM*,
DIOGENES, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2,
HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC,
PDLCOM*, PIRA, PROMT, RTECS*, SCISEARCH, SPECINFO, TOXCENTER, TULSA,
ULIDAT, USAN, USPAT2, USPATFULL, VETU, VTB

(*File contains numerically searchable property data)

Other Sources: DSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

DT.CA Cplus document type: Book; Conference; Dissertation; Journal; Patent;
Preprint; Report

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC
(Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);
PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role
in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC
(Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);
PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role
in record)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); CMBI (Combinatorial study); FORM (Formation, nonpreparative);
MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC
(Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses);
NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
study); BIOL (Biological study); CMBI (Combinatorial study); FORM
(Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence);

PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

/ Structure 1 in file .gra /

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

84039 REFERENCES IN FILE CA (1907 TO DATE)
22615 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
84192 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	6.87	7.08

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

FILE LAST UPDATED: 20 AUG 2005 (20050820/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11	
L2	185 L1
=> s PEG	
L3	9298 PEG 747 PEKS 9685 PEG (PEG OR PEKS)
=> s poly () ethylene () glycol	
	59257 POLY 6 POLIES 59263 POLY (POLY OR POLIES)
	18961 ETHYLENE 2287 ETHYLENES 19618 ETHYLENE (ETHYLENE OR ETHYLENES)
	22544 GLYCOL 27720 GLYCOLS 40275 GLYCOL (GLYCOL OR GLYCOLS)
L4	2487 POLY (W) ETHYLENE (W) GLYCOL
=> s methoxypoly () ethylene glycol	
	66 METHOXYPOLY

18961 ETHYLENE
2287 ETHYLENES
19618 ETHYLENE
(ETHYLENE OR ETHYLENES)
22544 GLYCOL
27720 GLYCOLS
40275 GLYCOL
(GLYCOL OR GLYCOLS)
8421 ETHYLENE GLYCOL
(ETHYLENE (W) GLYCOL)
L5 52 METHOXYPOLY (W) ETHYLENE GLYCOL

=> s 15 or 14 or 13
L6 10866 L5 OR L4 OR L3

=> s antibod?
L7 694206 ANTIBOD?

=> s clearance or clear or excret? or removed or removal
89107 CLEARANCE
5664 CLEARANCES
91341 CLEARANCE
(CLEARANCE OR CLEARANCES)
128624 CLEAR
549 CLEARS
129145 CLEAR
(CLEAR OR CLEARS)
116634 EXCRET?
99889 REMOVED
142890 REMOVAL
1080 REMOVALS
143364 REMOVAL
(REMOVAL OR REMOVALS)
L8 538410 CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL

=> s 18 and 16
L9 1041 L8 AND L6

=> s 19 and 17
L10 129 L9 AND L7

=> s anti-PEG
574125 ANTI
6 ANTIS
574129 ANTI
(ANTI OR ANTIS)
9298 PEG
747 PEGS
9685 PEG
(PEG OR PEGS)
L11 7 ANTI-PEG
(ANTI (W) PEG)

=> s l11 and 18
L12 2 L11 AND L8

=> d ibib 1-2

L12 ANSWER 1 OF 2 MEDLINE on STN
ACCESSION NUMBER: 2002229521 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11966757
TITLE: The in vivo effects of tumour necrosis factor blockade on the early cell mediated immune events and syndrome expression in rat adjuvant arthritis.
AUTHOR: Bush K A; Kirkham B W; Walker J S

CORPORATE SOURCE: School of Physiology & Pharmacology, University of New South Wales, NSW, Australia.
SOURCE: Clinical and experimental immunology, (2002 Mar) 127 (3)
423-9.
Journal code: 0057202. ISSN: 0009-9104.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020423
Last Updated on STN: 20020906
Entered Medline: 20020904

L12 ANSWER 2 OF 2 MEDLINE on STN
ACCESSION NUMBER: 2000191525 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10725103
TITLE: Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.
Cheng T L; Chen B M; Chern J W; Wu M F; Roffler S R
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
AUTHOR:
CORPORATE SOURCE:
SOURCE:
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200005
ENTRY DATE: Entered STN: 20000613
Last Updated on STN: 20000613
Entered Medline: 20000531

=> d his

(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
E "PEG"/CN 25

L1 1 S E3

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

L2 185 S L1
L3 9685 S PEG
L4 2487 S POLY () ETHYLENE () GLYCOL
L5 52 S METHOXPOLY () ETHYLENE GLYCOL
L6 10866 S L5 OR L4 OR L3
L7 694206 S ANTIBOD?
L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L9 1041 S L8 AND L6
L10 129 S L9 AND L7
L11 7 S ANTI-PEG
L12 2 S L11 AND L8

=> s l11 not py>1999
3085459 PY>1999
L13 3 L11 NOT PY>1999

=> d ibib 1-3

L13 ANSWER 1 OF 3 MEDLINE on STN
ACCESSION NUMBER: 1998089627 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9428158

TITLE: Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo.

AUTHOR: Jean-Francois J; D'Urso E M; Fortier G

CORPORATE SOURCE: Departement de Chimie-Biochimie, Universite du Quebec, Montreal, Canada.

SOURCE: Biotechnology and applied biochemistry, (1997 Dec) 26 (Pt 3) 203-12.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199802

ENTRY DATE: Entered STN: 19980217
Last Updated on STN: 20000303
Entered Medline: 19980205

L13 ANSWER 2 OF 3 MEDLINE on STN
ACCESSION NUMBER: 84160696 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6706424
TITLE: Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors.
AUTHOR: Richter A W; Akerblom E
SOURCE: International archives of allergy and applied immunology, (1984) 74 (1) 36-9.
Journal code: 0404561. ISSN: 0020-5915.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198405
ENTRY DATE: Entered STN: 19900319
Last Updated on STN: 19970203
Entered Medline: 19840522

L13 ANSWER 3 OF 3 MEDLINE on STN
ACCESSION NUMBER: 83107741 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6401699
TITLE: Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins.
AUTHOR: Richter A W; Akerblom E
SOURCE: International archives of allergy and applied immunology, (1983) 70 (2) 124-31.
Journal code: 0404561. ISSN: 0020-5915.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198303
ENTRY DATE: Entered STN: 19900318
Last Updated on STN: 19900318
Entered Medline: 19830311

=> d kwic 1

L13 ANSWER 1 OF 3 MEDLINE on STN
AB . . . spleen or liver. ELISA tests at 28 days and 120 days showed the presence of anti-ASNase (and, in lower amounts, anti-PEG) antibodies in sera of implanted rats. As observed with other enzyme-immobilization systems used in vivo, the formation of

fibroblast-like cell. . .

=> d kwic 2

L13 ANSWER 2 OF 3 MEDLINE on STN

AB . . . allergies and in healthy blood donors employing passive hemagglutination. In untreated allergic patients and in healthy blood donors, naturally occurring anti-PEG antibody titers between 32 and 512 were seen in 3.3 and 0.2%, respectively. During hyposensitization with monomethoxy polyethylene glycol modified ragweed extract and honey bee venom, respectively, the patients showed an anti-PEG antibody response. Titers of 32-512 were found in 50% of the patients directly after the first treatment course. After 2. . . years of treatment the percentage of patients with such titers declined to 28.5%. Mercaptoethanol treatment of sera indicated that the anti-PEG antibodies predominantly were of the IgM isotype. The weak IgM response found in treated patients is considered to be of. . .

=> d kwic 3

L13 ANSWER 3 OF 3 MEDLINE on STN

AB . . . protein and the degree of modification. With modified OA, in the presence of FCA, the majority of animals showed an anti-PEG response. With modified SOD and Rag only a small proportion of animals responded. In the absence of FCA, modified OA, given s.c., did not elicit any anti-PEG antibody response in rabbits and only a weak response in mice. PEG of MW 10,000 and 100,000 given in FCA. . . mice, showed no or very poor immunogenic properties. Gel diffusion, heterologous passive anaphylaxis and passive hemagglutination were used to demonstrate anti-PEG antibodies raised to PEG-modified proteins. Specificity was confirmed by hapten inhibition of precipitation, inhibition of passive hemagglutination and cross-reactivity tests.. . . by PEG of MW 300 it appears that the antigenic determinant of PEG may be a sequence of 6-7 -CH₂CH₂O-units. Anti-PEG antibodies can be used analytically. By gel diffusion, Peg was detected in minimal concentrations of 0.1-1 microgram/ml. The clinical relevance. . .

=> d ab 3

L13 ANSWER 3 OF 3 MEDLINE on STN

AB Antibodies to polyethylene glycol (PEG) were raised in rabbits by immunization with monomethoxy polyethylene glycol modified ovalbumin (OA), bovine superoxide dismutase (SOD), and ragweed pollen extract (Rag), given in Freund's complete adjuvant (FCA). Immunogenicity depended on the nature of the protein and the degree of modification. With modified OA, in the presence of FCA, the majority of animals showed an anti-PEG response. With modified SOD and Rag only a small proportion of animals responded. In the absence of FCA, modified OA, given s.c., did not elicit any anti-PEG antibody response in rabbits and only a weak response in mice. PEG of MW 10,000 and 100,000 given in FCA was found nonimmunogenic in rabbits, and PEG of MW 5.9 X 10(6), given s.c. to mice, showed no or very poor immunogenic properties. Gel diffusion, heterologous passive anaphylaxis and passive hemagglutination were used to demonstrate anti-PEG antibodies raised to PEG-modified proteins. Specificity was confirmed by hapten inhibition of precipitation, inhibition of passive hemagglutination and cross-reactivity tests. PEG of MW greater than or equal to 4,000 produced specific precipitates, smaller molecules acted as monovalent haptens. From hapten inhibition of precipitation by PEG of MW 300 it appears that the antigenic determinant of PEG may be a sequence of 6-7 -CH₂CH₂O-units. Anti

-PEG antibodies can be used analytically. By gel diffusion, Peg was detected in minimal concentrations of 0.1-1 microgram/ml. The clinical relevance of these findings with regard to therapy with PEG-modified enzymes and allergens in humans remains to be established.

=> d kwic

L13 ANSWER 1 OF 3 MEDLINE on STN

AB . . . spleen or liver. ELISA tests at 28 days and 120 days showed the presence of anti-ASNase (and, in lower amounts, anti-PEG) antibodies in sera of implanted rats. As observed with other enzyme-immobilization systems used in vivo, the formation of fibroblast-like cell. . .

=> d his

(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
E "PEG"/CN 25

L1 1 S E3

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

L2 185 S L1
L3 9685 S PEG
L4 2487 S POLY () ETHYLENE () GLYCOL
L5 52 S METHOXPOLY () ETHYLENE GLYCOL
L6 10866 S L5 OR L4 OR L3
L7 694206 S ANTIBOD?
L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L9 1041 S L8 AND L6
L10 129 S L9 AND L7
L11 7 S ANTI-PEG
L12 2 S L11 AND L8
L13 3 S L11 NOT PY>1999

=> s l10 not py>1999

3085459 PY>1999

L14 97 L10 NOT PY>1999

=> s l14 not py>1998

3546810 PY>1998

L15 90 L14 NOT PY>1998

=> s increase? or accelerat?

1841898 INCREASE?

88142 ACCELERAT?

L16 1898836 INCREASE? OR ACCELERAT?

=> s l16 and l15

L17 24 L16 AND L15

=> s l16 (S) 18

L18 51664 L16 (S) L8

=> s l18 and l17

L19 7 L18 AND L17

=> d ibib 1-4

L19 ANSWER 1 OF 7 MEDLINE on STN

ACCESSION NUMBER: 1998151177 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9492213

TITLE: Improved local delivery of TGF-beta2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol.
AUTHOR: Bentz H; Schroeder J A; Etridge T D
CORPORATE SOURCE: Research and Development, Collagen Corporation, Palo Alto, California 94303, USA.
SOURCE: Journal of biomedical materials research, (1998 Mar 15) 39 (4) 539-48.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199804
ENTRY DATE: Entered STN: 19980422
Last Updated on STN: 19980422
Entered Medline: 19980413

L19 ANSWER 2 OF 7 MEDLINE on STN
ACCESSION NUMBER: 97415461 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9271260
TITLE: Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
AUTHOR: Harding J A; Engbers C M; Newman M S; Goldstein N I; Zalipsky S
CORPORATE SOURCE: SEQUUS Pharmaceuticals, Incorporated, Menlo Park, CA 94025, USA.
SOURCE: Biochimica et biophysica acta, (1997 Jul 25) 1327 (2) 181-92.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199709
ENTRY DATE: Entered STN: 19970926
Last Updated on STN: 20000303
Entered Medline: 19970918

L19 ANSWER 3 OF 7 MEDLINE on STN
ACCESSION NUMBER: 95071855 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7981064
TITLE: The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
AUTHOR: Pedley R B; Boden J A; Boden R; Begent R H; Turner A; Haines A M; King D J
CORPORATE SOURCE: Department of Clinical Oncology, Royal Free Hospital School of Medicine, London, U.K.
SOURCE: British journal of cancer, (1994 Dec) 70 (6) 1126-30.
PUB. COUNTRY: SCOTLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199501
ENTRY DATE: Entered STN: 19950116
Last Updated on STN: 19980206
Entered Medline: 19950103

L19 ANSWER 4 OF 7 MEDLINE on STN
ACCESSION NUMBER: 92235285 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1569204
TITLE: IgG antibody response to polyethylene

glycol-modified adenosine deaminase in patients with
adenosine deaminase deficiency.
AUTHOR: Chaffee S; Mary A; Stiehm E R; Girault D; Fischer A;
Hershfield M S
CORPORATE SOURCE: Department of Medicine, Duke University Medical Center,
Durham, North Carolina 27710.
CONTRACT NUMBER: DK20902 (NIDDK)
SOURCE: Journal of clinical investigation, (1992 May) 89 (5)
1643-51.
Journal code: 7802877. ISSN: 0021-9738.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199205
ENTRY DATE: Entered STN: 19920612
Last Updated on STN: 19920612
Entered Medline: 19920526

=> d kwic 3

L19 ANSWER 3 OF 7 MEDLINE on STN
TI The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
AB Attachment of poly(ethylene glycol) (PEG) to proteins can greatly alter their pharmacological properties, including extending the plasma half-life and reducing immunogenicity, both of which are potentially beneficial to tumour targeting. IgG, F(ab')2 and Fab' fragments of the anti-CEA antibody A5B7 were chemically modified with PEG (M(r) 5,000), labelled with 125I and their pharmacokinetics compared with the unmodified forms in the LS174T colonic xenograft in nude mice. PEG modification of the intact antibody had little effect on biodistribution, although tumour localisation was slightly reduced. In contrast, similar modification of F(ab')2 and Fab'A5B7 significantly prolonged plasma half-life and increased radioantibody accumulation in the tumour and to a lesser extent in normal tissues, but reduced tissue to blood ratios. Prior to modification, Fab'A5B7 (M(r) 50,000) cleared more rapidly from the circulation than F(ab')2 (M(r) 100,000), but after PEG attachment their biodistributions converged, while the tumour to blood ratios were reduced and resembled that of the intact antibody. The enhanced tumour accumulation, reduced normal tissue to blood ratios and potentially reduced immunogenicity of fragments after PEG attachment may therefore prove superior to either unmodified fragments or intact antibody for antibody-targeted therapy, although the increased plasma half-life may necessitate the use of a clearance mechanism.
CT Check Tags: In Vitro
*Adenocarcinoma: IM, immunology
Animals
 Antibodies, Monoclonal: CH, chemistry
 *Antibodies, Monoclonal: ME, metabolism
*Carcinoembryonic Antigen: IM, immunology
*Colonic Neoplasms: IM, immunology
 Humans
 Immunoglobulins, Fab: ME, metabolism
 Mice
 Mice, Nude
 Neoplasm.
CN 0 (Antibodies, Monoclonal); 0 (Carcinoembryonic Antigen); 0 (Immunoglobulins, Fab); 0 (Polyethylene Glycols)

=> d kwic ibib 3

L19 ANSWER 3 OF 7 MEDLINE on STN

TI The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.

AB Attachment of poly(ethylene glycol) (PEG) to proteins can greatly alter their pharmacological properties, including extending the plasma half-life and reducing immunogenicity, both of which are potentially beneficial to tumour targeting. IgG, F(ab')2 and Fab' fragments of the anti-CEA antibody A5B7 were chemically modified with PEG (M(r) 5,000), labelled with 125I and their pharmacokinetics compared with the unmodified forms in the LS174T colonic xenograft in nude mice. PEG modification of the intact antibody had little effect on biodistribution, although tumour localisation was slightly reduced. In contrast, similar modification of F(ab')2 and Fab'A5B7 significantly prolonged plasma half-life and increased radioantibody accumulation in the tumour and to a lesser extent in normal tissues, but reduced tissue to blood ratios. Prior to modification, Fab' A5B7 (M(r) 50,000) cleared more rapidly from the circulation than F(ab')2 (M(r) 100,000), but after PEG attachment their biodistributions converged, while the tumour to blood ratios were reduced and resembled that of the intact antibody. The enhanced tumour accumulation, reduced normal tissue to blood ratios and potentially reduced immunogenicity of fragments after PEG attachment may therefore prove superior to either unmodified fragments or intact antibody for antibody-targeted therapy, although the increased plasma half-life may necessitate the use of a clearance mechanism.

CT Check Tags: In Vitro

*Adenocarcinoma: IM, immunology

Animals

Antibodies, Monoclonal: CH, chemistry

*Antibodies, Monoclonal: ME, metabolism

*Carcinoembryonic Antigen: IM, immunology

*Colonic Neoplasms: IM, immunology

Humans

Immunoglobulins, Fab: ME, metabolism

Mice

Mice, Nude

Neoplasm. . .

CN 0 (Antibodies, Monoclonal); 0 (Carcinoembryonic Antigen); 0 (Immunoglobulins, Fab); 0 (Polyethylene Glycols)

ACCESSION NUMBER: 95071855 MEDLINE

DOCUMENT NUMBER: PubMed ID: 7981064

TITLE: The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.

AUTHOR: Pedley R B; Boden J A; Boden R; Begent R H; Turner A; Haines A M; King D J

CORPORATE SOURCE: Department of Clinical Oncology, Royal Free Hospital School of Medicine, London, U.K.

SOURCE: British journal of cancer, (1994 Dec) 70 (6) 1126-30.
Journal code: 0370635. ISSN: 0007-0920.

PUB. COUNTRY: SCOTLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199501

ENTRY DATE: Entered STN: 19950116

Last Updated on STN: 19980206

Entered Medline: 19950103

=> d his

(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005

E "PEG"/CN 25

L1 1 S E3

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

L2 185 S L1

L3 9685 S PEG

L4 2487 S POLY () ETHYLENE () GLYCOL

L5 52 S METHOXYPOLY () ETHYLENE GLYCOL

L6 10866 S L5 OR L4 OR L3

L7 694206 S ANTIBOD?

L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL

L9 1041 S L8 AND L6

L10 129 S L9 AND L7

L11 7 S ANTI-PEG

L12 2 S L11 AND L8

L13 3 S L11 NOT PY>1999

L14 97 S L10 NOT PY>1999

L15 90 S L14 NOT PY>1998

L16 1898836 S INCREASE? OR ACCELERAT?

L17 24 S L16 AND L15

L18 51664 S L16 (S) L8

L19 7 S L18 AND L17

=> d ibib 5-7

L19 ANSWER 5 OF 7 MEDLINE on STN

ACCESSION NUMBER: 91334430 MEDLINE

DOCUMENT NUMBER: PubMed ID: 1714590

TITLE: Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol.

AUTHOR: Hershfield M S; Chaffee S; Koro-Johnson L; Mary A; Smith A A; Short S A

CORPORATE SOURCE: Department of Medicine, Duke University Medical Center, Durham, NC 27710.

CONTRACT NUMBER: DK20902 (NIDDK)

SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (1991 Aug 15) 88 (16) 7185-9. Journal code: 7505876. ISSN: 0027-8424.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

OTHER SOURCE: GENBANK-M60917; GENBANK-M66858; GENBANK-M66859;

GENBANK-M66860; GENBANK-M66861; GENBANK-M66862;

GENBANK-S45955; GENBANK-S45957; GENBANK-S45959;

GENBANK-S49265

ENTRY MONTH: 199109

ENTRY DATE: Entered STN: 19911006

Last Updated on STN: 19960129

Entered Medline: 19910918

L19 ANSWER 6 OF 7 MEDLINE on STN

ACCESSION NUMBER: 89391643 MEDLINE

DOCUMENT NUMBER: PubMed ID: 2789501

TITLE: Low avidity antibodies to double stranded DNA in systemic lupus erythematosus: a longitudinal study of their clinical significance.

AUTHOR: Nossent J C; Huysen V; Smeenk R J; Swaak A J

CORPORATE SOURCE: Department of Rheumatology, Dr Daniel den Hoed Clinic,
Rotterdam, The Netherlands.
SOURCE: Annals of the rheumatic diseases, (1989 Aug) 48 (8) 677-82.
Journal code: 0372355. ISSN: 0003-4967.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198910
ENTRY DATE: Entered STN: 19900309
Last Updated on STN: 19900309
Entered Medline: 19891020

L19 ANSWER 7 OF 7 MEDLINE on STN
ACCESSION NUMBER: 85003720 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6479199
TITLE: Association of circulating immune complexes with glomerular proteinuria in patients with transitional cell carcinoma of the urinary bladder.
AUTHOR: Skaarup P; Jensenius J C; Brandslund I; Svehag S E; Wolf H
SOURCE: European urology, (1984) 10 (4) 249-53.
Journal code: 7512719. ISSN: 0302-2838.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198411
ENTRY DATE: Entered STN: 19900320
Last Updated on STN: 19900320
Entered Medline: 19841101

=> d kwic 1

L19 ANSWER 1 OF 7 MEDLINE on STN
AB To overcome rapid diffusion and clearance from the implant site and to increase stability, recombinant transforming growth factor beta2 (TGF-beta2) was covalently bound to injectable bovine dermal fibrillar collagen (FC) and its activity. . . to admixed TGF-beta2. Covalent binding was achieved in a two-step procedure: First, TGF-beta2 was reacted with the difunctional polyethylene glycol (PEG) linker, and then the PEG-attached TGF-beta2 (PEG-TGF-beta2) was bound to the fibrillar collagen (FC-PEG-TGF-beta2). Initial binding of TGF-beta2 to difunctional succinimidyl glutarate (D-SG-PEG) or succinimidyl propionate polyethylene glycol (D-SE-PEG) linkers was completed after reacting for 8 or 10 min as monitored by reverse-phase high-performance liquid chromatography. After reaction with injectable fibrillar collagen, extraction of unbound PEG-TGF-beta2 and Western blot analysis, using a TGF-beta specific antibody, demonstrated that at least 85% of the TGF-beta2 was bound to the fibrillar collagen. The activity of PEG-TGF-beta2 was fully stable in phosphate-buffered saline at 4 degrees C and 37 degrees C for at least up to 4. . . inactivated after 1 week of incubation, as measured by the mink lung epithelial cell (Mv1Lu) growth inhibition assay. Formulations of FC-PEG-TGF-beta2 containing 40 microg/mL TGF-beta2 were implanted subcutaneously into rats and analyzed after days 7, 21, and 42. All TGF-beta2-containing. . . the TGF-beta typical fibroblastic response at the day 7 time point. Covalent binding of TGF-beta2 to collagen with both difunctional PEG crosslinkers resulted in a significantly stronger and longer-lasting TGF-beta2 response than that observed with admixed formulations of collagen and TGF-beta. The TGF-beta response with FC-PEG-TGF-beta2 lasted up to day 42 but was not seen after day 7 for TGF-beta2 admixed to FC. These findings clearly demonstrate that TGF-beta2 remains fully active after being covalently bound to collagen

via difunctional PEG. In addition, covalent binding potentiates and prolongs *in vivo* TGF-beta responses and stabilizes the TGF-beta *in vitro*. Results suggest that. . .

=> d kwic 2

L19 ANSWER 2 OF 7 MEDLINE on STN
TI Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
AB Immunoliposomes composed of hydrogenated soy phosphatidylcholine, cholesterol, methoxypoly(ethylene glycol)-distearoyl phosphatidylethanolamine (mPEG-DSPE), and hydrazide-PEG-DSPE (mole ratio, 57:38:3.3:1.7) linked to periodate-oxidized chimerized mouse IgG (C225, anti-human epidermal growth factor receptor) were prepared by an optimized. . . (MRT = 8.5 h, Cl = 0.2 ml/h). Subsequent injections of the immunoliposomes into the same animals resulted in rapid clearance (MRT < or = 0.7 h, Cl > or = 7 ml/h), which was accompanied by a significant increase in anti-C225 specific titers. Upon repeated injection or coinjection with the parent liposomes free C225 consistently exhibited prolonged circulation without any increase in C225-specific antisera, but was cleared quickly when administered into animals that had been pretreated with the immunoliposomes. Screening of. . . the immune response was specifically triggered by the constant human region of C225. These results demonstrate that the preparations of PEG-grafted immunoliposomes are more immunogenic than the free IgG component, which is of profound importance to the antibody-mediated liposomal drug delivery effort.
CT Check Tags: Male
Animals
Antibodies, Monoclonal: AD, administration & dosage
Antibodies, Monoclonal: IM, immunology
*Drug Delivery Systems
Enzyme-Linked Immunosorbent Assay
Flow Cytometry
Humans
Immunoglobulins, Fab: ME, metabolism
*Liposomes: IM, immunology
CN 0 (Antibodies, Monoclonal); 0 (Immunoglobulins, Fab); 0 (Liposomes); 0 (Phosphatidylethanolamines); 0 (Polyethylene Glycols); EC 2.7.1.112 (Receptor, Epidermal Growth Factor)

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 9.14 16.22

FILE 'CAPLUS' ENTERED AT 08:17:28 ON 23 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Aug 2005 VOL 143 ISS 9
FILE LAST UPDATED: 22 Aug 2005 (20050822/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s PEG
33003 PEG
1125 PEGS
L20 33476 PEG
(PEG OR PEGS)

=> s poly () ethylene () glycol
644812 POLY
2 POLIES
644813 POLY
(POLY OR POLIES)
506522 ETHYLENE
3337 ETHYLENES
507988 ETHYLENE
(ETHYLENE OR ETHYLENES)
334892 GLYCOL
44021 GLYCOLS
349919 GLYCOL
(GLYCOL OR GLYCOLS)
L21 12996 POLY (W) ETHYLENE (W) GLYCOL

=> s methoxypoly () ethylene glycol
228 METHOXYPOLY
506522 ETHYLENE
3337 ETHYLENES
507988 ETHYLENE
(ETHYLENE OR ETHYLENES)
334892 GLYCOL
44021 GLYCOLS
349919 GLYCOL
(GLYCOL OR GLYCOLS)
122310 ETHYLENE GLYCOL
(ETHYLENE (W) GLYCOL)
L22 144 METHOXYPOLY (W) ETHYLENE GLYCOL

=> s 122 or 121 or 120
L23 41717 L22 OR L21 OR L20

=> s antibod?
L24 440322 ANTIBOD?

=> s clearance or clear or excret? or removed or removal
67750 CLEARANCE
5064 CLEARANCES
69883 CLEARANCE
(CLEARANCE OR CLEARANCES)
191308 CLEAR
942 CLEARS
192117 CLEAR
(CLEAR OR CLEARS)
158408 EXCRET?
390380 REMOVED
620820 REMOVAL
5047 REMOVALS
622011 REMOVAL
(REMOVAL OR REMOVALS)

L25 1304988 CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
=> s clearance or clear? or excret? or removed or removal
67750 CLEARANCE
5064 CLEARANCES
69883 CLEARANCE
(CLEARANCE OR CLEARANCES)
422339 CLEAR?
158408 EXCRET?
390380 REMOVED
620820 REMOVAL
5047 REMOVALS
622011 REMOVAL
(REMOVAL OR REMOVALS)

L26 1459976 CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
=> s increase? or accelerat?
3483178 INCREASE?
330235 ACCELERAT?
L27 3736368 INCREASE? OR ACCELERAT?
75% OF LIMIT FOR TOTAL ANSWERS REACHED

=> s 126 (S) 127
L28 99738 L26 (S) L27

=> s 124 and 128
L29 1750 L24 AND L28

=> s 129 and 123
L30 16 L29 AND L23

=> s anti-PEG
378223 ANTI
9 ANTIS
378230 ANTI
(ANTI OR ANTIS)
33003 PEG
1125 PEGS
33476 PEG
(PEG OR PEGS)

L31 9 ANTI-PEG
(ANTI(W) PEG)

=> s 131 not py>1999
5788970 PY>1999
L32 3 L31 NOT PY>1999

=> d ibib 1-3

L32 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:239090 CAPLUS
DOCUMENT NUMBER: 131:63325
TITLE: Accelerated Clearance of Polyethylene Glycol-Modified Proteins by Anti-Polyethylene Glycol IgM
AUTHOR(S): Cheng, Tian-Lu; Wu, Pin-Yi; Wu, Ming-Fang; Chern, Ji-Wang; Roffler, Steve R.
CORPORATE SOURCE: Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
SOURCE: Bioconjugate Chemistry (1999), 10(3), 520-528
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:24552 CAPLUS
DOCUMENT NUMBER: 128:162592
TITLE: Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo
AUTHOR(S): Jean-Francois, Jacques; D'urso, Edith Marie; Fortier, Guy
CORPORATE SOURCE: Laboratoire d'Enzymologie Appliquee, Departement de Chimie-Biochimie, Universite du Quebec, Montreal, Montreal, QC, H3C 3P8, Can.
SOURCE: Biotechnology and Applied Biochemistry (1997), 26(3), 203-212
CODEN: BABIEC; ISSN: 0885-4513
PUBLISHER: Portland Press Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1983:15249 CAPLUS
DOCUMENT NUMBER: 98:15249
TITLE: Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol-modified proteins
AUTHOR(S): Richter, Ary Wolfgang; Aakerblom, Eva
CORPORATE SOURCE: Dep. Biomed. Res., Pharm. AB, Uppsala, 75104, Swed.
SOURCE: International Archives of Allergy and Applied Immunology (1983), 70(2), 124-31
CODEN: IAAAM; ISSN: 0020-5915
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
E "PEG"/CN 25

L1 1 S E3

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

L2 185 S L1
L3 9685 S PEG
L4 2487 S POLY () ETHYLENE () GLYCOL
L5 52 S METHOXYPOLY () ETHYLENE GLYCOL
L6 10866 S L5 OR L4 OR L3
L7 694206 S ANTIBOD?
L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L9 1041 S L8 AND L6
L10 129 S L9 AND L7
L11 7 S ANTI-PEG
L12 2 S L11 AND L8
L13 3 S L11 NOT PY>1999
L14 97 S L10 NOT PY>1999
L15 90 S L14 NOT PY>1998
L16 1898836 S INCREASE? OR ACCELERAT?
L17 24 S L16 AND L15
L18 51664 S L16 (S) L8
L19 7 S L18 AND L17

FILE 'CAPLUS' ENTERED AT 08:17:28 ON 23 AUG 2005

L20 33476 S PEG
L21 12996 S POLY () ETHYLENE () GLYCOL
L22 144 S METHOXYPOLY () ETHYLENE GLYCOL
L23 41717 S L22 OR L21 OR L20
L24 440322 S ANTIBOD?
L25 1304988 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L26 1459976 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L27 3736368 S INCREASE? OR ACCELERAT?
L28 99738 S L26 (S) L27
L29 1750 S L24 AND L28
L30 16 S L29 AND L23
L31 9 S ANTI-PEG
L32 3 S L31 NOT PY>1999

=> s l30 not py>1998
6611305 PY>1998
L33 6 L30 NOT PY>1998

=> d ibib 1-3

L33 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:90995 CAPLUS
DOCUMENT NUMBER: 128:196557
TITLE: Improved local delivery of TGF- β 2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol
AUTHOR(S): Bentz, H.; Schroeder, J. A.; Estridge, T. D.
CORPORATE SOURCE: Research and Development, Collagen Corporation, Palo Alto, CA, 94303, USA
SOURCE: Journal of Biomedical Materials Research (1998), 39(4), 539-548
CODEN: JBMRBG; ISSN: 0021-9304
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:463486 CAPLUS
DOCUMENT NUMBER: 127:99686
TITLE: Immunogenicity-pharmacokinetics relationship of polyethylene glycol-grafted immunoliposomes
AUTHOR(S): Zalipsky, S.; Harding, J. A.; Engbers, C. M.; Newman, M. S.; Goldstein, N. I.
CORPORATE SOURCE: SEQUUS Pharmaceuticals, Inc., Menlo Park, CA, 94025, USA
SOURCE: Proceedings of the International Symposium on Controlled Release of Bioactive Materials (1997), 24th, 87-88
CODEN: PCRMEY; ISSN: 1022-0178
PUBLISHER: Controlled Release Society, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

L33 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:420003 CAPLUS
DOCUMENT NUMBER: 127:140290
TITLE: Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes
AUTHOR(S): Harding, Jennifer A.; Engbers, Charles M.; Newman, Mary S.; Goldstein, Neil I.; Zalipsky, Samuel
CORPORATE SOURCE: SEQUUS Pharmaceuticals, Incorporated, 960 Hamilton Court, Menlo Park, USA

SOURCE: Biochimica et Biophysica Acta (1997), 1327(2), 181-192
CODEN: BBACAO; ISSN: 0006-3002
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic 2

L33 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AB Preps. of site-specifically constructed, aggregation free PEG -grafted immunoliposomes are more immunogenic than free C225 antibodies (Ab). This immunogenicity potentiation was almost entirely due to the constant human Fc region of the Ab. Presence of C225-specific Ab's in the immunoliposome-treated rats dramatically accelerated clearance of subsequently injected immunoliposomes or free C225. Negligible response to the Fab portion of conjugated C225 was detected, suggesting that use of Fab' as a targeting moiety on PEG-liposomes is less likely to cause immunogenicity related problems. These observations are of importance to antibody-mediated liposomal drug delivery.
ST immunoliposome PEG grafted antibody
IT Epidermal growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study) (antibodies to; immunogenicity-pharmacokinetics relationship of polyethylene glycol-grafted immunoliposomes)
IT Polyoxyalkylenes, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (derivs., conjugates with C225 antibody; immunogenicity-pharmacokinetics relationship of polyethylene glycol-grafted immunoliposomes)
IT Antibodies
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (to EGF receptor, conjugates with PEG derivs.; immunogenicity-pharmacokinetics relationship of polyethylene glycol-grafted immunoliposomes)
IT 25322-68-3D, Peg, derivs., conjugates with C225 antibody
171115-99-4D, derivs., conjugates with C225 antibody
178744-28-0D, derivs., conjugates with C225 antibody
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (immunogenicity-pharmacokinetics relationship of polyethylene glycol-grafted immunoliposomes)

=> d kwic 3

L33 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
TI Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes
AB Immunoliposomes composed of hydrogenated soy phosphatidylcholine, cholesterol, methoxypoly(ethylene glycol)-distearoyl phosphatidylethanolamine (mPEG-DSPE), and hydrazide-PEG-DSPE (mole ratio, 57:38:3.3:1.7) linked to periodate-oxidized chimerized mouse IgG (C225, anti-human epidermal growth factor receptor) were prepared by an optimized. . . (MRT = 8.5 h, Cl = 0.2 mL/h). Subsequent injections of the immunoliposomes into the same animals resulted in rapid clearance (MRT≤0.7 h, Cl≥7 mL/h), which was accompanied by a significant increase in anti-C225 specific titers. Upon repeated injection or coinjection with the parent liposomes free C225 consistently exhibited prolonged

circulation without any increase in C225-specific antisera, but was cleared quickly when administered into animals that had been pretreated with the immunoliposomes. Screening of the immunoliposome induced antisera against human. . . the immune response was specifically triggered by the constant human region of C225. These results demonstrate that the preps. of PEG-grafted immunoliposomes are more immunogenic than the free IgG component, which is of profound importance to the antibody-mediated liposomal drug delivery effort.

- ST immunoliposome PEG grafted; pharmacokinetics immunoliposome
PEG grafted
- IT Immunoglobulins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(G; immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes)
- IT Epidermal growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibodies to; immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes)
- IT Phosphatidylcholines, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes)
- IT Drug delivery systems
(immunoliposomes; immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes)
- IT Polyoxyalkylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(reaction products with distearoylphosphatidylethanolamine, hydrazide derivative; immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes)
- IT 4537-76-2DP, Distearoylphosphatidylethanolamine, reaction products with PEG derivs. 9004-74-4DP, Methoxypolyethylene glycol, reaction products with distearoylphosphatidylethanolamine 25322-68-3DP, PEG, reaction products with distearoylphosphatidylethanolamine, hydrazide derivative
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes)

=> d ibib 4-6

L33 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:292108 CAPLUS
DOCUMENT NUMBER: 122:75593
TITLE: The potential for enhanced tumor localization by poly(ethylene glycol) modification of anti-CEA antibody
AUTHOR(S): Pedley, R. B.; Boden, J. A.; Boden, R.; Begent, R. H. J.; Turner, A.; Haines, A. M. R.; King, D. J.
CORPORATE SOURCE: Department Clinical Oncology, Royal Free Hospital School Medicine, London, NW3 2PF, UK
SOURCE: British Journal of Cancer (1994), 70(6), 1126-30
CODEN: BJCAAI; ISSN: 0007-0920

DOCUMENT TYPE: Journal
LANGUAGE: English

L33 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:250975 CAPLUS
DOCUMENT NUMBER: 118:250975
TITLE: Radioimmunoassay for the pyridinoline crosslinked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation
AUTHOR(S): Risteli, Juha; Elomaa, Inkeri; Niemi, Seija; Novamo, Anne; Risteli, Leila
CORPORATE SOURCE: Dep. Med. Biochem., Univ. Oulu, Oulu, SF-90220, Finland
SOURCE: Clinical Chemistry (Washington, DC, United States) (1993), 39(4), 635-40
CODEN: CLCHAU; ISSN: 0009-9147

DOCUMENT TYPE: Journal
LANGUAGE: English

L33 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:550137 CAPLUS
DOCUMENT NUMBER: 115:150137
TITLE: Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol
AUTHOR(S): Hershfield, Michael S.; Chaffee, Sara; Koro-Johnson, Lillian; Mary, Ann; Smith, Albert A.; Short, Steven A.
CORPORATE SOURCE: Med. Cent., Duke Univ., Durham, NC, 27710, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1991), 88(16), 7185-9
CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal
LANGUAGE: English

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	62.60	78.82
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

FILE 'PCTFULL' ENTERED AT 08:22:07 ON 23 AUG 2005
COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED: 22 AUG 2005 <20050822/UP>
MOST RECENT UPDATE WEEK: 200533 <200533/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s PEG
33330 PEG
4725 PEWS
L34 35377 PEG
(PEG OR PEWS)

=> s poly () ethylene () glycol
106749 POLY
281 POLIES
107011 POLY
(POLY OR POLIES)
94414 ETHYLENE

486 ETHYLENES
94496 ETHYLENE
(ETHYLENE OR ETHYLENES)
99346 GLYCOL
38678 GLYCOLS
106001 GLYCOL
(GLYCOL OR GLYCOLS)
L35 5321 POLY (W) ETHYLENE (W) GLYCOL

=> s methoxypoly () ethylene glycol
179 METHOXYPOLY
94414 ETHYLENE
486 ETHYLENES
94496 ETHYLENE
(ETHYLENE OR ETHYLENES)
99346 GLYCOL
38678 GLYCOLS
106001 GLYCOL
(GLYCOL OR GLYCOLS)
34591 ETHYLENE GLYCOL
(ETHYLENE (W) GLYCOL)
L36 76 METHOXYPOLY (W) ETHYLENE GLYCOL

=> s antibod?
L37 80487 ANTIBOD?

=> s clearance or clear? or excret? or removed or removal
40394 CLEARANCE
3516 CLEARANCES
41825 CLEARANCE
(CLEARANCE OR CLEARANCES)
285091 CLEAR?
16591 EXCRET?
339076 REMOVED
14 REMOVEDS
339079 REMOVED
(REMOVED OR REMOVEDS)
186688 REMOVAL
807 REMOVALS
186876 REMOVAL
(REMOVAL OR REMOVALS)
L38 492783 CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL

=> s increase? or accelerat?
477801 INCREASE?
83290 ACCELERAT?
L39 496097 INCREASE? OR ACCELERAT?

=> s 138 (S) 139
L40 83462 L38 (S) L39

=> s anti-PEG
159836 ANTI
158 ANTIS
159865 ANTI
(ANTI OR ANTIS)
33330 PEG
4725 PEGS
35377 PEG
(PEG OR PEGS)
L41 7 ANTI-PEG
(ANTI (W) PEG)

=> s 141 and 140
L42 5 L41 AND L40

=> d ibib 1-3

L42 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2005072385 PCTFULL ED 20050816 EW 200532
TITLE (ENGLISH): PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP)
RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL
METHODS OF USE
TITLE (FRENCH): AGONISTES DU RECEPTEUR (VPAC2) DU TYPE PEPTIDES
ACTIVANT L'ADENYLATE CYCLASE HYPOPHYSAIRE (PACAP) ET
PROCEDES PHARMACOLOGIQUES D'UTILISATION DE CES
AGONISTES
INVENTOR(S): CLAIRMONT, Kevin, 80 Merwin Circle, Cheshire,
Connecticut 06410, US [US, US];
LUMB, Kevin, J., 520 Granite Road, Guilford,
Connecticut 06437, US [US, US];
BUCKHOLZ, Thomas, 10 Morehouse Avenue, Milford,
Connecticut 06460, US [US, US];
SALHANICK, Arthur, I., 430 Bellevue Road, New Haven,
Connecticut 06511, US [US, US]
PATENT ASSIGNEE(S): BAYER PHARMACEUTICALS CORPORATION, 400 Morgan Lane,
West Haven, Connecticut 06516, US [US, US], for all
designates States except US;
CLAIRMONT, Kevin, 80 Merwin Circle, Cheshire,
Connecticut 06410, US [US, US], for US only;
LUMB, Kevin, J., 520 Granite Road, Guilford,
Connecticut 06437, US [US, US], for US only;
BUCKHOLZ, Thomas, 10 Morehouse Avenue, Milford,
Connecticut 06460, US [US, US], for US only;
SALHANICK, Arthur, I., 430 Bellevue Road, New Haven,
Connecticut 06511, US [US, US], for US only
AGENT: GREENMAN, Jeffrey, M.S., Bayer Pharmaceuticals
Corporation, 400 Morgan Lane, West Haven, Connecticut
06516\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2005072385 A2 20050811
DESIGNATED STATES
W:
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO
CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR
HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO
RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
VC VN YU ZA ZM ZW
RW (ARIPO): BW GH GM KE LS MW NA SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT
LT LU MC NL PL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2005-US2609 A 20050127
PRIORITY INFO.: US 2004-60/539,550 20040127
US 2004-60/566,499 20040429

L42 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2005016974 PCTFULL ED 20050302 EW 200508
TITLE (ENGLISH): SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND
CONJUGATION
TITLE (FRENCH): DERIVE D'ACIDE SIALIQUE DESTINE A LA DERIVATISATION ET
A LA CONJUGAISON PROTEINIQUE
INVENTOR(S): JAIN, Sanjay, Lipoxen Technologies Limited, Suite 303,
Hamilton House, Mabledon Place, London WC1H 9BB, GB

[IN, GB];
LAING, Peter, Lipoxen Technologies Limited, Suite 303,
Hamilton House, Mabledon Place, London WC1H 9BB, GB
[GB, GB];
GREGORIADIS, Gregory, Lipoxen Technologies Limited,
Suite 303, Hamilton House, Mabledon Place, London WC1H
9BB, GB [CA, GB];
HRECZUK-HRIST, Dale, Howard, Lipoxen Technologies
Limited, Suite 303, Hamilton House, Mabledon Place,
London WC1H 9BB, GB [GB, GB];
PAPAOANNOU, Yiannis, Lipoxen Technologies Limited,
Suite 303, Hamilton House, Mabledon Place, London WC1H
9BB, GB [GR, GB]
PATENT ASSIGNEE(S): LIPOXEN TECHNOLOGIES LIMITED, Suite 303, Hamilton
House, Mabledon Place, London WC1H 9BB, GB [GB, GB],
for all designates States except US;
JAIN, Sanjay, Lipoxen Technologies Limited, Suite 303,
Hamilton House, Mabledon Place, London WC1H 9BB, GB
[IN, GB], for US only;
LAING, Peter, Lipoxen Technologies Limited, Suite 303,
Hamilton House, Mabledon Place, London WC1H 9BB, GB
[GB, GB], for US only;
GREGORIADIS, Gregory, Lipoxen Technologies Limited,
Suite 303, Hamilton House, Mabledon Place, London WC1H
9BB, GB [CA, GB], for US only;
HRECZUK-HRIST, Dale, Howard, Lipoxen Technologies
Limited, Suite 303, Hamilton House, Mabledon Place,
London WC1H 9BB, GB [GB, GB], for US only;
PAPAOANNOU, Yiannis, Lipoxen Technologies Limited,
Suite 303, Hamilton House, Mabledon Place, London WC1H
9BB, GB [GR, GB], for US only

AGENT:

LANGUAGE OF FILING:

GILL JENNINGS & EVERY\$, Broadgate House, 7 Eldon
Street, London EC2M 7LHS, GB

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

English

PATENT INFORMATION:

Patent

NUMBER	KIND	DATE
WO 2005016974	A1	20050224

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO
CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR
HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO
RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
VC VN YU ZA ZM ZW

BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

RW (AR IPO): AM AZ BY KG KZ MD RU TJ TM

RW (EA IPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU

RW (EPO): MC NL PL PT RO SE SI SK TR

RW (O API): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2004-GB3511 A 20040812

PRIORITY INFO.: EP 2003-03254989.1 20030812

L42 ANSWER 3 OF 5

PCTFULL COPYRIGHT 2005 Univentio on STN

ACCESSION NUMBER: 2005016973 PCTFULL ED 20050302 EW 200508

TITLE (ENGLISH): POLYSIALIC ACID DERIVATIVES

TITLE (FRENCH): DERIVES D'ACIDE POLYSIALIQUE

INVENTOR(S): HRECZUK-HRIST, Dale, Howard, Lipoxen Technologies

Limited, Suite 303, Hamilton House, Mabledon Place,

London WC1H 9BB, GB [GB, GB];

JAIN, Sanjay, Lipoxen Technologies Limited, Suite 303,

Hamilton House, Mabledon Place, London WC1H 9BB, GB

[IN, GB];

PATENT ASSIGNEE(S): LAING, Peter, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GB, GB]; GREGORIADIS, Gregory, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [CA, GB]; PAPAIOANNOU, Iaannis, Lipoxon Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GR, GB] LIPOXEN TECHNOLOGIES LIMITED, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GB, GB], for all designates States except US; HREczuk-Hirst, Dale, Howard, Lipoxon Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GB, GB], for US only; JAIN, Sanjay, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [IN, GB], for US only; LAING, Peter, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GB, GB], for US only; GREGORIADIS, Gregory, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [CA, GB], for US only; PAPAIOANNOU, Iaannis, Lipoxon Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GR, GB], for US only
AGENT: GILL JENNINGS & EVERYS, Broadgate House, 7 Eldon Street, London EC2M 7LHS, GB

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2005016973	A1	20050224

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2004-GB3488 A 20040812
PRIORITY INFO.: EP 2003-03254988.3 20030812
EP 2003-03255200.2 20030821

=> d ibib 4-5

L42 ANSWER 4 OF 5
ACCESSION NUMBER: PCTFULL COPYRIGHT 2005 Univentio on STN
TITLE (ENGLISH): 2004030617 PCTFULL ED 20040421 EW 200416
POLYMER CONJUGATES WITH DECREASED ANTIGENICITY,
METHODS OF PREPARATION AND USES THEREOF
CONJUGUES DE POLYMERES AVEC ANTIGENICITE REDUITE,
PROCEDES DE PREPARATION ET UTILISATIONS DE CES
CONJUGUES
INVENTOR(S): MARTINEZ, Alexa, L., 1944 Jonathan Avenue, San Jose, CA 95125, US;
SHERMAN, Merry, R., 1114 Royal Lane, San Carlos, CA

94070, US;
SAIFER, Mark, G., P., 1114 Royal Lane, San Carlos, CA
94070, US;
WILLIAMS, L. David, 37709 Arlene Court, Fremont, CA
94536, US
PATENT ASSIGNEE(S): MOUNTAIN VIEW PHARMACEUTICALS, INC., 3475-S Edison Way,
Menlo Park, CA 94025, US [US, US]
AGENT: GOLDSTEIN, Jorge A.S, Sterne, Kessler, Goldstein & Fox,
P.L.L.C., 1100 New York Avenue, N.W., Washington, DC
20005\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2004030617	A2	20040415

DESIGNATED STATES
W:
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU
ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA
MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC
SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU
ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2003-US29989 A 20030925
PRIORITY INFO.: US 2002-60/414,424 20020930
US 2002-10/317,092 20021212

L42 ANSWER 5 OF 5
ACCESSION NUMBER: PCTFULL COPYRIGHT 2005 Univentio on STN
2001015726 PCTFULL ED 20020828
TITLE (ENGLISH): COMPOSITIONS FOR STIMULATING CYTOKINE SECRETION AND
INDUCING AN IMMUNE RESPONSE
TITLE (FRENCH): COMPOSITIONS STIMULANT LA SECRETION DE CYTOKINE ET
PROVOQUANT UNE REACTION IMMUNITAIRE
INVENTOR(S): SEMPLE, Sean, C.;
HARASYM, Troy, O.;
KLIMUK, Sandra, K.;
KOJIC, Ljiljiana, D.;
BRAMSON, Jonathan, L.;
MUI, Barbara;
HOPE, Michael, J.
PATENT ASSIGNEE(S): INEX PHARMACEUTICALS CORP.;
SEMPLE, Sean, C.;
HARASYM, Troy, O.;
KLIMUK, Sandra, K.;
KOJIC, Ljiljiana, D.;
BRAMSON, Jonathan, L.;
MUI, Barbara;
HOPE, Michael, J.

DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2001015726 A2 20010308

DESIGNATED STATES
W:
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD

SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG
CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2000-CA1013 A 20000828
PRIORITY INFO.: US 1999-60/151,211 19990827
US 2000-60/176,406 20000113

=> d his

(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
E "PEG"/CN 25

L1 1 S E3

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

L2 185 S L1
L3 9685 S PEG
L4 2487 S POLY () ETHYLENE () GLYCOL
L5 52 S METHOXPOLY () ETHYLENE GLYCOL
L6 10866 S L5 OR L4 OR L3
L7 694206 S ANTIBOD?
L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L9 1041 S L8 AND L6
L10 129 S L9 AND L7
L11 7 S ANTI-PEG
L12 2 S L11 AND L8
L13 3 S L11 NOT PY>1999
L14 97 S L10 NOT PY>1999
L15 90 S L14 NOT PY>1998
L16 1898836 S INCREASE? OR ACCELERAT?
L17 24 S L16 AND L15
L18 51664 S L16 (S) L8
L19 7 S L18 AND L17

FILE 'CAPLUS' ENTERED AT 08:17:28 ON 23 AUG 2005

L20 33476 S PEG
L21 12996 S POLY () ETHYLENE () GLYCOL
L22 144 S METHOXPOLY () ETHYLENE GLYCOL
L23 41717 S L22 OR L21 OR L20
L24 440322 S ANTIBOD?
L25 1304988 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L26 1459976 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L27 3736368 S INCREASE? OR ACCELERAT?
L28 99738 S L26 (S) L27
L29 1750 S L24 AND L28
L30 16 S L29 AND L23
L31 9 S ANTI-PEG
L32 3 S L31 NOT PY>1999
L33 6 S L30 NOT PY>1998

FILE 'PCTFULL' ENTERED AT 08:22:07 ON 23 AUG 2005

L34 35377 S PEG
L35 5321 S POLY () ETHYLENE () GLYCOL
L36 76 S METHOXPOLY () ETHYLENE GLYCOL
L37 80487 S ANTIBOD?
L38 492783 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L39 496097 S INCREASE? OR ACCELERAT?
L40 83462 S L38 (S) L39
L41 7 S ANTI-PEG
L42 5 S L41 AND L40

=> s 134 or 135 or 136
L43 38102 L34 OR L35 OR L36

=> s 143 (S) 137
L44 3934 L43 (S) L37

=> s 144 and 140
L45 1413 L44 AND L40

=> s 144 (P) 140
L46 1018 L44 (P) L40

=> s anti-(polyethylene glycol)

MISSING OPERATOR 'ANTI-(POLYETHYLENE'

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s anti () (polyethylene glycol)

159836 ANTI

158 ANTIS

159865 ANTI

(ANTI OR ANTIS)

123593 POLYETHYLENE

5298 POLYETHYLENES

124334 POLYETHYLENE

(POLYETHYLENE OR POLYETHYLENES)

99346 GLYCOL

38678 GLYCOLS

106001 GLYCOL

(GLYCOL OR GLYCOLS)

62856 POLYETHYLENE GLYCOL

(POLYETHYLENE(W)GLYCOL)

L47 3 ANTI (W) (POLYETHYLENE GLYCOL)

=> d ibib 1-3

L47 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2005016974 PCTFULL ED 20050302 EW 200508
TITLE (ENGLISH): SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION
TITLE (FRENCH): DERIVE D'ACIDE SIALIQUE DESTINE A LA DERIVATISATION ET A LA CONJUGAISON PROTEINIQUE
INVENTOR(S): JAIN, Sanjay, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [IN, GB]; LAING, Peter, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GB, GB]; GREGORIADIS, Gregory, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [CA, GB]; HREczuk-Hrist, Dale, Howard, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GB, GB]; PAPAOANNOU, Yiannis, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GR, GB]
PATENT ASSIGNEE(S): LIPOXEN TECHNOLOGIES LIMITED, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GB, GB], for all designates States except US; JAIN, Sanjay, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [IN, GB], for US only; LAING, Peter, Lipoxen Technologies Limited, Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB, GB [GB, GB], for US only; GREGORIADIS, Gregory, Lipoxen Technologies Limited,

Suite 303, Hamilton House, Mabledon Place, London WC1H
9BB, GB [CA, GB], for US only;
HRECZUK-HIRST, Dale, Howard, Lipoxen Technologies
Limited, Suite 303, Hamilton House, Mabledon Place,
London WC1H 9BB, GB [GB, GB], for US only;
PAPAOANNOU, Yiannis, Lipoxen Technologies Limited,
Suite 303, Hamilton House, Mabledon Place, London WC1H
9BB, GB [GR, GB], for US only
GILL JENNINGS & EVERY\$, Broadgate House, 7 Eldon
Street, London EC2M 7LH\$, GB

AGENT:

LANGUAGE OF FILING:
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2005016974	A1	20050224

DESIGNATED STATES
W:
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO
CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR
HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO
RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
VC VN YU ZA ZM ZW
BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
AM AZ BY KG KZ MD RU TJ TM
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
MC NL PL PT RO SE SI SK TR
BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
WO 2004-GB3511 A 20040812
EP 2003-03254989.1 20030812

RW (ARIPO):
RW (EAPO):
RW (EPO):
RW (OAPI):
APPLICATION INFO.:
PRIORITY INFO.:

L47 ANSWER 2 OF 3
ACCESSION NUMBER: 2005016973
TITLE (ENGLISH): POLYSIALIC ACID DERIVATIVES
TITLE (FRENCH): DERIVES D'ACIDE POLYSIALIQUE
INVENTOR(S): HRECZUK-HIRST, Dale, Howard, Lipoxen Technologies
Limited, Suite 303, Hamilton House, Mabledon Place,
London WC1H 9BB, GB [GB, GB];
JAIN, Sanjay, Lipoxen Technologies Limited, Suite 303,
Hamilton House, Mabledon Place, London WC1H 9BB, GB
[IN, GB];
LAING, Peter, Lipoxen Technologies Limited, Suite 303,
Hamilton House, Mabledon Place, London WC1H 9BB, GB
[GB, GB];
GREGORIADIS, Gregory, Lipoxen Technologies Limited,
Suite 303, Hamilton House, Mabledon Place, London WC1H
9BB, GB [CA, GB];
PAPAOANNOU, Iaonnis, Lipoxen Technologies Limited,
Suite 303, Hamilton House, Mabledon Place, London WC1H
9BB, GB [GR, GB]
PATENT ASSIGNEE(S): LIPOXEN TECHNOLOGIES LIMITED, Suite 303, Hamilton
House, Mabledon Place, London WC1H 9BB, GB [GB, GB],
for all designates States except US;
HRECZUK-HIRST, Dale, Howard, Lipoxen Technologies
Limited, Suite 303, Hamilton House, Mabledon Place,
London WC1H 9BB, GB [GB, GB], for US only;
JAIN, Sanjay, Lipoxen Technologies Limited, Suite 303,
Hamilton House, Mabledon Place, London WC1H 9BB, GB
[IN, GB], for US only;
LAING, Peter, Lipoxen Technologies Limited, Suite 303,
Hamilton House, Mabledon Place, London WC1H 9BB, GB
[GB, GB], for US only;
GREGORIADIS, Gregory, Lipoxen Technologies Limited,
Suite 303, Hamilton House, Mabledon Place, London WC1H

9BB, GB [CA, GB], for US only;
 PAPAOANNOU, Iaonnis, Lipoxon Technologies Limited,
 Suite 303, Hamilton House, Mabledon Place, London WC1H
 9BB, GB [GR, GB], for US only.
AGENT:
LANGUAGE OF FILING:
LANGUAGE OF PUBL.:
DOCUMENT TYPE:
PATENT INFORMATION:
 9BB, GB [CA, GB], for US only;
 PAPAOANNOU, Iaonnis, Lipoxon Technologies Limited,
 Suite 303, Hamilton House, Mabledon Place, London WC1H
 9BB, GB [GR, GB], for US only.
GILL JENNINGS & EVERY\$, Broadgate House, 7 Eldon
Street, London EC2M 7LH\$, GB
 English
 English
 Patent

NUMBER	KIND	DATE
WO 2005016973	A1	20050224

DESIGNATED STATES
W:
 AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO
 CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR
 HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
 MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO
 RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
 VC VN YU ZA ZM ZW
 BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
 AM AZ BY KG KZ MD RU TJ TM
 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
 MC NL PL PT RO SE SI SK TR
 BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:
PRIORITY INFO.:
 WO 2004-GB3488 A 20040812
 EP 2003-03254988.3 20030812
 EP 2003-03255200.2 20030821

 L47 ANSWER 3 OF 3
ACCESSION NUMBER:
 2004022000 PCTFULL ED 20040324 EW 200412
TITLE (ENGLISH):
 ANTIBIOTIC MICROSPHERES FOR TREATMENT OF INFECTIONS AND
 OSTEOMYELITIS
TITLE (FRENCH):
 MICROSPHERES ANTIBIOTIQUES POUR LE TRAITEMENT
 D'INFECTIONS ET DE L'OSTEOMYELITE
INVENTOR(S):
 AMBROSE, Catherine, G., 6431 Fannin, Houston, TX 77030,
 US [US, US];
 CLYBURN, Terry, A, 6431 Fannin, Houston, TX 77030, US
 [US, US];
 MIKOS, Antonios, G., P.O. Box 1892, Houston, TX 77251,
 US [US, US]
 AMBROSE, Catherine, G., 6431 Fannin, Houston, TX 77030,
 US [US, US];
 CLYBURN, Terry, A, 6431 Fannin, Houston, TX 77030, US
 [US, US];
 MIKOS, Antonios, G., P.O. Box 1892, Houston, TX 77251,
 US [US, US]
PATENT ASSIGNEE(S):
 RODDY, Kenneth, A.\$, Suite 100, 2916 West T.C. Jester,
 Houston, TX 77018\$, US
AGENT:
LANGUAGE OF FILING:
LANGUAGE OF PUBL.:
DOCUMENT TYPE:
PATENT INFORMATION:
 English
 English
 Patent

NUMBER	KIND	DATE
WO 2004022000	A2	20040318

DESIGNATED STATES
W:
 AE AG AL AU BA BB BR BZ CA CN CO CR CU DM DZ EC GD GE
 HR ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX
 NI NO NZ OM PG PH PL SC SG SY TN TT UA UZ VC VN YU ZA
 GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 AM AZ BY KG KZ MD RU TJ TM
 AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
 MC NL PL PT RO SE SI SK TR
 BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2003-US28010 A 20030905
PRIORITY INFO.: US 2002-60/408,496 20020905
US 2002-60/408,502 20020905

=> d his

(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
E "PEG"/CN 25

L1 1 S E3

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

L2 185 S L1
L3 9685 S PEG
L4 2487 S POLY () ETHYLENE () GLYCOL
L5 52 S METHOXYPOLY () ETHYLENE GLYCOL
L6 10866 S L5 OR L4 OR L3
L7 694206 S ANTIBOD?
L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L9 1041 S L8 AND L6
L10 129 S L9 AND L7
L11 7 S ANTI-PEG
L12 2 S L11 AND L8
L13 3 S L11 NOT PY>1999
L14 97 S L10 NOT PY>1999
L15 90 S L14 NOT PY>1998
L16 1898836 S INCREASE? OR ACCELERAT?
L17 24 S L16 AND L15
L18 51664 S L16 (S) L8
L19 7 S L18 AND L17

FILE 'CAPLUS' ENTERED AT 08:17:28 ON 23 AUG 2005

L20 33476 S PEG
L21 12996 S POLY () ETHYLENE () GLYCOL
L22 144 S METHOXYPOLY () ETHYLENE GLYCOL
L23 41717 S L22 OR L21 OR L20
L24 440322 S ANTIBOD?
L25 1304988 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L26 1459976 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L27 3736368 S INCREASE? OR ACCELERAT?
L28 99738 S L26 (S) L27
L29 1750 S L24 AND L28
L30 16 S L29 AND L23
L31 9 S ANTI-PEG
L32 3 S L31 NOT PY>1999
L33 6 S L30 NOT PY>1998

FILE 'PCTFULL' ENTERED AT 08:22:07 ON 23 AUG 2005

L34 35377 S PEG
L35 5321 S POLY () ETHYLENE () GLYCOL
L36 76 S METHOXYPOLY () ETHYLENE GLYCOL
L37 80487 S ANTIBOD?
L38 492783 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L39 496097 S INCREASE? OR ACCELERAT?
L40 83462 S L38 (S) L39
L41 7 S ANTI-PEG
L42 5 S L41 AND L40
L43 38102 S L34 OR L35 OR L36
L44 3934 S L43 (S) L37
L45 1413 S L44 AND L40
L46 1018 S L44 (P) L40
L47 3 S ANTI () (POLYETHYLENE GLYCOL)

=> s 146 not py>1999
 581472 PY>1999
 L48 282 L46 NOT PY>1999

=> s 143/ab

662 PEG/AB
 227 PEGS/AB
 831 PEG/AB
 ((PEG OR PEGS) /AB)
 3882 POLY/AB
 132 POLIES/AB
 4014 POLY/AB
 ((POLY OR POLIES) /AB)
 6371 ETHYLENE/AB
 22 ETHYLENES/AB
 6377 ETHYLENE/AB
 ((ETHYLENE OR ETHYLENES) /AB)
 3431 GLYCOL/AB
 453 GLYCOLS/AB
 3707 GLYCOL/AB
 ((GLYCOL OR GLYCOLS) /AB)
 122 POLY/AB (W) ETHYLENE/AB (W) GLYCOL/AB
 0 METHOXYPOLY/AB
 6371 ETHYLENE/AB
 22 ETHYLENES/AB
 6377 ETHYLENE/AB
 ((ETHYLENE OR ETHYLENES) /AB)
 3431 GLYCOL/AB
 453 GLYCOLS/AB
 3707 GLYCOL/AB
 ((GLYCOL OR GLYCOLS) /AB)
 604 ETHYLENE GLYCOL/AB
 ((ETHYLENE (W) GLYCOL) /AB)
 0 METHOXYPOLY/AB (W) ETHYLENE GLYCOL/AB
 L49 930 ((PEG/AB) OR (POLY/AB (W) ETHYLENE/AB (W) GLYCOL/AB) OR (METHOXY
 POLY/AB (W) ETHYLENE GLYCOL/AB))

=> s 149 and 148
 L50 12 L49 AND L48

=> s 150 not py>1998
 649032 PY>1998
 L51 11 L50 NOT PY>1998

=> d ibib 1-5

L51 ANSWER 1 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 1998048837 PCTFULL ED 20020514
 TITLE (ENGLISH): POLYALKYLENE OXIDE-MODIFIED SINGLE CHAIN POLYPEPTIDES
 TITLE (FRENCH): POLYPEPTIDES A CHAINE UNIQUE MODIFIES PAR OXYDE DE
 POLYALKYLENE
 INVENTOR(S): WHITLOW, Marc;
 SHORR, Robert, G., L.;
 FILPULA, David, R.;
 LEE, Lihsyng, S.
 PATENT ASSIGNEE(S): ENZON, INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9848837	A1	19981105

DESIGNATED STATES
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC

LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
 KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
 CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
 CF CG CI CM GA GN ML MR NE SN TD TG
 WO 1998-US8654 A 19980430
 US 1997-60/044,449 19970430
 US 1997-60/050,472 19970623
 US 1997-60/063,074 19971027
 US 1997-60/067,341 19971202

APPLICATION INFO.:
 PRIORITY INFO.:
 ACCESSION NUMBER:
 TITLE (ENGLISH):
 TITLE (FRENCH):
 INVENTOR(S):
 PATENT ASSIGNEE(S):
 LANGUAGE OF PUBL.:
 DOCUMENT TYPE:
 PATENT INFORMATION:

PCTFULL COPYRIGHT 2005 Univentio on STN
 1998044143 PCTFULL ED 20020514
 POLYMER-MODIFIED VIRUSES
 VIRUS MODIFIES PAR DES POLYMERES
 SMITH, Alan, E.;
 O'RIORDAN, Catherine, R.;
 FRANCIS, Gillian, E.;
 PARKES, Vincent;
 DELGADO, Christina
 GENZYME CORPORATION;
 POLYMASC PHARMACEUTICAL, PLC;
 SMITH, Alan, E.;
 O'RIORDAN, Catherine, R.;
 FRANCIS, Gillian, E.;
 PARKES, Vincent;
 DELGADO, Christina
 English
 Patent

DESIGNATED STATES
 W:
 AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
 GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
 BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
 BJ CF CG CI CM GA GN ML MR NE SN TD TG
 WO 1998-US6609 A 19980403
 GB 1997-9706735.9 19970403
 GB 1997-9719625.7 19970915
 GB 1997-9722316.8 19971022

APPLICATION INFO.:
 PRIORITY INFO.:
 ACCESSION NUMBER:
 TITLE (ENGLISH):
 TITLE (FRENCH):
 INVENTOR(S):
 PATENT ASSIGNEE(S):
 LANGUAGE OF PUBL.:
 DOCUMENT TYPE:
 PATENT INFORMATION:

PCTFULL COPYRIGHT 2005 Univentio on STN
 1997010847 PCTFULL ED 20020514
 TARGETING OF CONJUGATES OF POLY(ETHYLENE GLYCOL) AND
 ANTIBODIES AGAINST GLUTAMIC ACID DECARBOXYLASE TO ISLET
 CELLS
 CIBLAGE DE CONJUGUES DE POLY(ETHYLENE GLYCOL) ET
 D'ANTICORPS CONTRE L'ACIDE GLUTAMIQUE DECARBOXYLASE SUR
 DES CELLULES INSULAIRES
 JACOBS, Harvey;
 KIM, Sung, Wan;
 MENARD, Virginie
 UNIVERSITY OF UTAH RESEARCH FOUNDATION
 English
 Patent

DESIGNATED STATES
 NUMBER KIND DATE
 WO 9710847 A1 19970327

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT
 LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI
 SK TJ TM TR TT UA UG UZ VN KE LS MW SD SZ UG AM AZ BY
 KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT
 LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD
 TG
 APPLICATION INFO.: WO 1996-US15219 A 19960920
 PRIORITY INFO.: US 1995-60/004,109 19950921

 L51 ANSWER 4 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 1997003092 PCTFULL ED 20020514
 TITLE (ENGLISH): A PROCESS FOR REMOVAL OF POLYETHYLENE GLYCOL FROM A
 PROTEIN OR PEPTIDE SOLUTION
 TITLE (FRENCH): PROCEDE POUR ELIMINER LE POLYETHYLENEGLYCOL D'UNE
 SOLUTION DE PROTEINES OU DE PEPTIDES
 INVENTOR(S): KAERSGAARD, Per;
 CARLSEN, Soren, Knud
 PATENT ASSIGNEE(S): HEMASURE A/S;
 KAERSGAARD, Per;
 CARLSEN, Soren, Knud
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9703092	A1	19970130

 DESIGNATED STATES
 W: JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
 SE
 APPLICATION INFO.: WO 1996-DK314 A 19960710
 PRIORITY INFO.: DK 1995-823/95 19950713
 DK 1995-970/95 19950904

 L51 ANSWER 5 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 1996034015 PCTFULL ED 20020514
 TITLE (ENGLISH): MODIFIED ANTI-ICAM-1 ANTIBODIES AND THEIR USE IN THE
 TREATMENT OF INFLAMMATION
 TITLE (FRENCH): ANTICORPS ANTI-ICAM-1 MODIFIES ET LEUR UTILISATION DANS
 LE TRAITEMENT DES INFLAMMATIONS
 INVENTOR(S): FAANES, Ronald, B.;
 MC GOFF, Paul, E.;
 SHIRLEY, Bret, A.;
 SCHER, David, S.
 PATENT ASSIGNEE(S): BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.;
 FAANES, Ronald, B.;
 MC GOFF, Paul, E.;
 SHIRLEY, Bret, A.;
 SCHER, David, S.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9634015	A1	19961031

 DESIGNATED STATES
 W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI
 GB GE HU IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
 MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR
 TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD
 RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL
 PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
 APPLICATION INFO.: WO 1996-US5550 A 19960423
 PRIORITY INFO.: US 1995-8/427,355 19950424

=> d kwic 4

L51 ANSWER 4 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ABEN Polyethylene is used for fractional precipitation of proteins and peptides. Protein and peptide fractions obtained by the PEG fractionation methods generally contains residual PEG. The invention relates to a process for removing contaminating PEG from a solution of proteins or peptides, which process comprises adsorption of PEG in the protein or peptide solution to activated carbon.

ABFR . . . fractionnaire des proteines et des peptides. Les fractions de proteines et de peptides obtenues selon les methodes de fractionnement par PEG contiennent generalement des residus de PEG. La presente invention concerne un procede permettant d'eliminer d'une solution de proteines ou de peptides le PEG contaminant, lequel procede consiste a adsorber le PEG contenu dans la solution sur un carbone active.

DETD . . . application having publication number 123,375 describes manufacturing of a dry γ -globulin preparation capable of intravenous injection by fractionating human plasma with PEG. The method provides a γ -globulin preparation with improved water solubility and stability against increase of anticomplementary activity and decrease of antibody titer.

In one aspect of this invention, the activated carbon is added to the PEG-containing protein or peptide solution batchwise, and after. . . PEG, the activated carbon is separated from the solution by methods known per se such as centrifugation, sedimentation, or filtration. The removed activated carbon may subsequently be washed and the washing solution may be added to the purified, more protein or peptide containing solution, to increase the recovery of, for example, a valuable protein or peptide in the purified solution.

carbon filter with a flow rate that permits the adsorbtion of the PEG to the activated carbon in the filter. The removal of the PEG by filtration may be combined with the removal of other contaminating substances, with a decolorization, or with a clarification of the solution by the activated carbon filter. The filtration. . . may subsequently be washed and the washing solution may be added to the purified more protein or peptide containing solution, to increase the recovery of e.g. a valuable protein or peptide in the treated solution.

=> d kwic 3

L51 ANSWER 3 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ABEN . . . coupled to a nonimmunogenic hydrophilic polymer that provides a hydration shell around the monoclonal antibody for inhibiting immune recognition thereof. Poly(ethylene glycol) is a preferred polymer. A method of reducing insulitis in an IDDM patient and a composition

therefor are also described.
ABFR . . . non immunogene
qui forme une enveloppe d'hydratation autour de l'anticorps monoclonal
en vue d'inhiber la
reconnaissance immune de celui-ci. Le poly(ethylene
glycol) est un polymere preferé. L'invention se
rapporte également à un procede de reduction de l'insulite chez un
patient atteint d'IDDM, . . .

DETD TARGETING OF CONJUGATES OF POLY(ETHYLENE
GLYCOL) AND ANTIBODIES AGAINST
GLUTAMIC ACID DECARBOXYLASE TO ISLET CELLS 11
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S.

From an immunotherapeutic approach, overt early stage diabetes has been treated by blocking the activating receptors on T cells with monoclonal antibodies. In one such study, anti-lymphocyte serum (ALS) and antibodies directed against CD4 and Cd8 T cell receptors were administered to diabetic mice. T. Maki et al., Long-term Abrogation of Autoimmune Diabetes. . . within 30 days after treatment and lasted for about 200 days. Several significant points about the autoimmunity of diabetes were observed. The lymphocytic antibodies were responsible for termination of the immune response, thereby allowing islet recovery. Also, if antibody BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS FIG. 1 shows the reactions for coupling methoxy-PEG-amine to an F(ab') fragment with a heterobifunctional crosslinker.

Preferably, the polymer is a poly (ethylene glycol), and more preferably has a molecular weight in the range of about 200 to 8,000, although higher molecular weight polymers, branched polymers, star molecules, and PEG block copolymers are also within the scope of the invention. Methoxy-PEG is a particularly preferred polymer. It is also preferred that the monoclonal antibody or fragment thereof is an F (ab I) fragment.

In the present invention, anti-GAD monoclonal antibodies (Mab) are modified to maintain binding to their cognate antigens while further preventing recognition by other aspects of the immune system. In an illustrative embodiment, the anti-GAD antibody is modified by digestion with a protease and chemical reduction with a reducing agent to yield F(ab') fragments, which are then conjugated with various poly(ethylene glycol) polymers (PEG). The F(ab') fragment retains the antigen-specific Fab binding fragment, while the immune and complement activating Fc fragment is removed. In addition, the poly(ethylene glycol) moiety provides an increased hydration sphere and dynamic mobility that prevents protein and cellular interaction. Thus, the present anti-GAD-F(ab')-PEG composition simultaneously binds GAD and prevents or inhibits further recognition by the immune system.

Antibodies administered to experimental animals and

hydrophilic surfaces, due to the hydrating effect of PEG. More importantly, protein (albumin and other plasma proteins) adsorption was greatly reduced, resulting from the high chain motility, hydration sphere, and protein exclusion properties of PEG.

pH 7.3) and then incubated in 250 Al of blocking buffer for 1 hour at 370C. After incubation, the blocking buffer was removed and the Immunol. 98-104 (1978), hereby incorporated by reference. To further increase the immune reactivity of the F(ab') fragment, poly(ethylene glycol) (PEG) is conjugated to the F(abl) molecule. PEG is a linear or branched, neutral.

ascites fluid was microplate was dried. Duplicate dilutions (50 141) of samples containing anti-GAD (IgG, F (ab') , or F (abl) -PEG) (serum or dilutions of chromatographic fractions) were placed in the wells and incubated for 2 hours at 370C, followed by 3 washes with . . . microplate autoreader (EL311, is Bio-Tek Instruments) . These values were compared to standard curves prepared with known anti-GAD concentrations to extrapolate the anti-GAD antibody concentration.

either Example 1 or Example 2 was enzymatically digested and then chemically reduced to obtain F(abl) fragments, which could then be coupled to PEG. The rationale behind this procedure is to obtain an antibody fragment capable of binding to the GAD antigen yet which lacks the Fc domain, and is conjugated with PEG to further decrease protein and cellular interactions.

It was anticipated that the antibodies isolated during the previous procedures were a mixture of anti-GAD and indigenous mouse antibodies. As a final antigenicity of foreign immunogenic proteins and enzymes. Therefore, PEGs of various molecular weights are coupled to the F(ab') fragments through the sulphydryl groups thereof. These anti-GAD-F(ab')-PEG compositions maintain ability to bind to islet/beta cells while the PEG moiety masks the remainder of the F(ab') molecule from eliciting additional immunological events.

Example 8

Coupling of Anti-GAD-F(abl) to Activated PEG
In this example, a PEG intermediate prepared according to the procedure of Examples 4, 6, or 7 is Example 5

Activation of Diamino-PEG

For cell staining and whole body perfusion (pharmacokinetic) evaluations, it is useful to label anti-GAD-F(abl)-PEG with, for example, a radioactive or fluorescent label. In vivo therapeutic applications of the anti-GAD-F(abl)-PEG generally do not require such labels. Current methods of labeling antibodies involve forming conjugates through amine groups (fluorescent or 125I labels) or through oxidation of tyrosine residues (125, label) These labeling methods can interfere with antibody binding through reaction with the active site of the antibody. Therefore, this example shows coupling of the label to the PEG moiety. The labeled PEG

moiety
is later coupled to the F (ab I) fragment. This procedure
assures that labeled and unlabeled compositions have
similar affinities for. . .

=> d his

(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
E "PEG"/CN 25

L1 1 S E3

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

L2 185 S L1
L3 9685 S PEG
L4 2487 S POLY () ETHYLENE () GLYCOL
L5 52 S METHOXPOLY () ETHYLENE GLYCOL
L6 10866 S L5 OR L4 OR L3
L7 694206 S ANTIBOD?
L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L9 1041 S L8 AND L6
L10 129 S L9 AND L7
L11 7 S ANTI-PEG
L12 2 S L11 AND L8
L13 3 S L11 NOT PY>1999
L14 97 S L10 NOT PY>1999
L15 90 S L14 NOT PY>1998
L16 1898836 S INCREASE? OR ACCELERAT?
L17 24 S L16 AND L15
L18 51664 S L16 (S) L8
L19 7 S L18 AND L17

FILE 'CAPLUS' ENTERED AT 08:17:28 ON 23 AUG 2005

L20 33476 S PEG
L21 12996 S POLY () ETHYLENE () GLYCOL
L22 144 S METHOXPOLY () ETHYLENE GLYCOL
L23 41717 S L22 OR L21 OR L20
L24 440322 S ANTIBOD?
L25 1304988 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L26 1459976 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L27 3736368 S INCREASE? OR ACCELERAT?
L28 99738 S L26 (S) L27
L29 1750 S L24 AND L28
L30 16 S L29 AND L23
L31 9 S ANTI-PEG
L32 3 S L31 NOT PY>1999
L33 6 S L30 NOT PY>1998

FILE 'PCTFULL' ENTERED AT 08:22:07 ON 23 AUG 2005

L34 35377 S PEG
L35 5321 S POLY () ETHYLENE () GLYCOL
L36 76 S METHOXPOLY () ETHYLENE GLYCOL
L37 80487 S ANTIBOD?
L38 492783 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L39 496097 S INCREASE? OR ACCELERAT?
L40 83462 S L38 (S) L39
L41 7 S ANTI-PEG
L42 5 S L41 AND L40
L43 38102 S L34 OR L35 OR L36
L44 3934 S L43 (S) L37
L45 1413 S L44 AND L40
L46 1018 S L44 (P) L40
L47 3 S ANTI () (POLYETHYLENE GLYCOL)

L48 282 S L46 NOT PY>1999
L49 930 S L43/AB
L50 12 S L49 AND L48
L51 11 S L50 NOT PY>1998

=> d ibib 6-10

L51 ANSWER 6 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1994029370 PCTFULL ED 20020513
TITLE (ENGLISH): FACTOR IX - POLYMERIC CONJUGATES
TITLE (FRENCH): CONJUGUES POLYMERES MODIFIANT L'ACTIVITE DU FACTEUR IX
INVENTOR(S): HALLAHAN, Terrence, W.;
GILBERT, Carl, W.
PATENT ASSIGNEE(S): ENZON, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9429370	A1	19941222

DESIGNATED STATES

W:

AU BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL PT
RO RU SE SK UA AT BE CH DE DK ES FR GB GR IE IT LU MC
NL PT SE

APPLICATION INFO.: WO 1994-US6388 A 19940607
PRIORITY INFO.: US 1993-8/073,531 19930608

L51 ANSWER 7 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1994022429 PCTFULL ED 20020513
TITLE (ENGLISH): SOLID-TUMOR TREATMENT METHOD
TITLE (FRENCH): PROCEDE DE TRAITEMENT D'UNE TUMEUR SOLIDE
INVENTOR(S): ALLEN, Theresa, M.;
MARTIN, Francis, J.;
WOODLE, Martin, C.;
ZALIPSKY, Samuel

PATENT ASSIGNEE(S): LIPOSOME TECHNOLOGY, INC.;
ALLEN, Theresa, M.;
MARTIN, Francis, J.;
WOODLE, Martin, C.;
ZALIPSKY, Samuel

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9422429	A1	19941013

DESIGNATED STATES

W:

AU CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL
PT SE

APPLICATION INFO.: WO 1994-US3457 A 19940330
PRIORITY INFO.: US 1993-8/040,544 19930331

L51 ANSWER 8 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1994015625 PCTFULL ED 20020513
TITLE (ENGLISH): FACTOR VIII - POLYMERIC CONJUGATES
TITLE (FRENCH): CONJUGUES DE POLYMERES ET DE FACTEUR VIII
INVENTOR(S): HALLAHAN, Terrence, W.;
GILBERT, Carl, W.

PATENT ASSIGNEE(S): ENZON, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9415625	A1	19940721

DESIGNATED STATES
 W: AU BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL PT
 RO RU SE SK UA AT BE CH DE DK ES FR GB GR IE IT LU MC
 NL PT SE
 APPLICATION INFO.: WO 1994-US552 A 19940113
 PRIORITY INFO.: US 1993-8/003, 985 19930115

L51 ANSWER 9 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 1993000109 PCTFULL ED 20020513
 TITLE (ENGLISH): METHOD OF STIMULATING IMMUNE RESPONSE USING GROWTH
 HORMONE
 TITLE (FRENCH): PROCEDE DE STIMULATION DE LA REPONSE IMMUNITAIRE A
 L'AIDE D'HORMONE DE CROISSANCE
 INVENTOR(S): CARLSSON, Lena, Mariana, Susann;
 CLARK, Ross, G.;
 CRONIN, Michael, J.;
 JARDIEU, Paula, M.
 GENENTECH, INC.
 PATENT ASSIGNEE(S): English
 LANGUAGE OF PUBL.: Patent
 DOCUMENT TYPE:
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9300109	A1	19930107

DESIGNATED STATES
 W: AU CA JP AT BE CH DE DK ES FR GB GR IT LU MC NL SE
 APPLICATION INFO.: WO 1992-US4489 A 19920529
 PRIORITY INFO.: US 1991-723, 359 19910628

L51 ANSWER 10 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 1990004606 PCTFULL ED 20020513
 TITLE (ENGLISH): A PROCESS FOR FRACTIONATING POLYETHYLENE GLYCOL
 (PEG)-PROTEIN ADDUCTS AND AN ADDUCT OF PEG AND
 GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR
 TITLE (FRENCH): PROCEDE DE FRACTIONNEMENT DE PRODUITS D'ADDITION DE
 PROTEINE-POLYETHYLENE GLYCOL (PEG) AINSI QU'UN PRODUIT
 D'ADDITION DE PEG ET UNFACTEUR DE STIMULATION DE
 COLONIES DE GRANULOCYTES-MACROPHAGES
 INVENTOR(S): FISHER, Derek;
 FRANCIS, Gillian, Elizabeth;
 DELGADO, Cristina
 PATENT ASSIGNEE(S): ROYAL FREE HOSPITAL SCHOOL OF MEDICINE;
 FISHER, Derek;
 FRANCIS, Gillian, Elizabeth;
 DELGADO, Cristina
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE:
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9004606	A1	19900503

DESIGNATED STATES
 W: AT BE CH DE FR GB IT JP LU NL SE US
 APPLICATION INFO.: WO 1989-GB1261 A 19891020
 PRIORITY INFO.: GB 1988-8824591.5 19881020

=> d kwic 7

L51 ANSWER 7 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
 ABEN . . . composition has sizes predominantly in the range 0.05 to 0.12
 microns,
 includes doxorubicin in entrapped form, and contains, on the PEG
 free ends, a monoclonal antibody
 specific against highly proliferative cells in a lung squamous cell

carcinoma.

ABFR . . . fois le temps de circulation dans le sang desdits liposomes par rapport a celui de liposomes depourvus de cette couche PEG. Des anticorps ou fragments d'anticorps (16), efficaces pour se lier specifiquement aux antigenes associes a la tumeur, presents sur le. . . entre 0,05 et 0,12 microns, renferme de la doxorubicine sous forme piegee, et contient, sur les extremites libres des chaines PEG, un anticorps monoclonal specifiquement dirige contre des cellules fortement proliferatives d'un epithelioma epidermoide bronchique.

DETD . . . accompanying figures and examples,

Brief Description of the Figures

Fig* 1 illustrates a portion of a liposome in the liposome ocomposition of the invention, having antibodies or antibody fragments attached to the free ends of polyethylene glycol (PEG) chains carried on the liposome;

Fig 2 shows steps in forming a PE derivatized by a PEG spacer chain having a maleimide group at its free end;

Fig 3 illustrates the preparation of a biotinylated PE-PEG for use in preparing liposomes with PEG-bound biotin;

Fig. 4 shows coupling of an antibody to PE derivatized with a PEG chain having a hydrazide moiety at its free end;

Fig. 5 shows the coupling of an antibody to PE derivatized by a PEG chain having a reactive maleimide group at its free end;

Fig. 6 shows the coupling of an antibody to a liposome-attached PEG having a hydrazide group at its free end;

Fig* 7 is a plot of drug residence time in the blood, expressed in terms of percent injected dose, as a function of hours after IV injection in rats, for liposomes containing 67Gallium and a bound antibody IgG (9) or liposomes with no bound antibody (A);

Fig o 8 shows 125dUrd uptake in normal and tumor-bearing DBA/2 mice (3/group) 45 days after i.v. injection of 2 x 105. . .

This embodiment allows the antibody in the polymer layer to be positioned at a selected depth in the layer to increase or decrease the extent to which the antibody is buried in the polymer layer.. For example, if the antibody is a xenogeneic antibody which elicits an immunogenic-response the antibody is preferably buried to hide immunogenic sites while retaining the antigen recognition region accessible for binding to a target site. If the antibody is nonimmunogenic, the antibody can be localized on the outer surface coating of polyethylene glycol chains'. Functionalization of PEG chains for this purpose, referred to herein as a spacer chain, for attachment of an antibody is described below.

In another embodiment the antibody is a biotinylated antibody attached to the distal ends of liposome-attached polymer ends via a biotin-

streptavidin (or biotin-avidin) linkage. In one embodiment, shown in Fig. 3, a DSPE-PEG-NH₂ is converted to DSPE-PEG-biotin. To the biotin moiety on the PEG free ends are bound avidin or streptavidin molecules. Each avidin molecule contains four high-affinity biotin binding sites and to one or more of these sites is attached the liposome bound biotin. To one or more of the free-remaining sites can be bound a biotinylated antibody which is derivatized by a biotin molecule.

The liposomes are then incubated with avidin and biotinylated antibody.

Alternatively, a DSPE derivatized with a PEG chain having a hydrazide group at the chain's free end may be synthesized, as illustrated in Fig. 4*. Here, a hydroxy acid derivative (IX) is prepared from PEG using ethyl isocyanatoacetate for partial introduction of a urethane-linked glycine residue.

30-75 percent vesicle-forming lipids, 25-40 percent cholesterol, 1-20 percent polymer-derivatized lipid, and 0.10 mole percent of the lipid derivative employed for antibody coupling, one exemplary liposome formulation includes hydrogenated soy phosphatidylethanolamine (HSPE), cholesterol (CH), DSPE-PEG at a molar ratio of 2:1:0.1. The composition also includes 0.05 mole percent phosphatidylethanolamine derivatized with biotin (biotin-PE). Another exemplary liposome formulation includes hydrogenated soy phosphatidylethanolamine (HSPE), cholesterol (CH), and DSPE-PEG at a molar ratio of 2:1:0. The composition also includes 1 mole percent DSPE-PEG derivatized with hydrazide (DSPE-PEG-Hz).

Alternatively, an antibody-lipid derivative may be first formed and then incorporated into a liposome. As an example, an antibody is coupled to the maleimide group of a free DSPE-PEG molecule. The antibody-coupled DSPE-PEG molecule is then employed to form vesicles.

Alternatively, the polymer end-functionalized group is a hydrazide group (see Figure 4 discussed above). Conveniently, the hydrazide can be coupled to the antibody through the carbohydrate moieties present in the antibody, as detailed in Figure 6 and Example 1.VIII. Briefly, antibody hydroxyl groups are oxidized to aldehydes by mild periodate oxidation. The oxidized protein is then added to liposomes containing DSPE-PEG-Hz and incubated overnight. Unbound antibodies are then separated from antibody-liposomes by gel filtration.

Ive Utility

According to an important aspect of the invention, it has been found that antibodies can be attached to the PEG chain free ends without a significant loss in the blood circulation lifetime of the liposomes. This allows the antibody-coated liposomes to circulate for the time necessary to reach remote tumor sites and to localize at the

sites through antibody-antigen specific interactions. As a result, a significant therapeutic enhancement in tumor treatment over long-circulating liposomes in the absence of surface attached antibodies is possible.

A, Therapeutic Efficacy of Antibody-liposome Composition in vivo

Experiments were performed to investigate the half-life in the bloodstream and the tissue biodistribution of the antibody]liposome composition. For these experiments liposomes containing PEG end-functionalized with a hydrazide group covalently linked to sheep IgG were prepared as described in Example 1.VIII.

The tissue biodistribution of liposomes containing ^{125}I -tyraminylinulin with and without covalently attached IgG antibodies is shown in Table I (Example 2(I)). It can be seen that the tissue biodistribution of liposomes containing antibody covalently attached to the end of a PEG chain by a hydrazide group is very similar to those of liposomes containing nonfunctionalized PEG chains. Liposome biodistribution was determined for the blood, liver, spleen, lung,, heart and carcass.

Other experiments to determine the blood circulation times of antibody-liposomes were performed using liposomes containing surface-bound avidin and biotinylated antibodies. Liposomes with surface-bound antibodies possessed long circulation times in the bloodstream similar to that of liposomes containing PEG derivatized lipids but lacking the surface-bound antibodies.

Twenty-four hours post-injection 34.7 ± 6.7% of
WO 94/22429 PCTIUS94/03457

20

mAb liposomes were in the blood. This level is comparable to that of liposomes containing PEG, but lacking the antibody (37.5 ± 9.7% at 24 hours).

The results obtained indicate that liposomes containing entrapped doxorubicin, lipids derivatized with PEG, such as PEG]DSPE, and containing an antibody on the liposomes' outer surface (mAb-liposomal DOX) are valuable for increasing the therapeutic effectiveness of doxorubicin administration to a site in a subject.

compound,
multivalent species capable of binding multiple antibodies may be administered between about 24 to 48 hours after administration of the biotinylated antibodies to accelerate clearance of the antibodies from the bloodstream. These multivalent species may be empty liposomes having surface-bound avidin, but not containing the liposome-entrapped compound, The empty.

These multivalent species serve to chase nonspecifically-bound biotinylated antibodies from

sites in the bloodstream. After the chase, liposomes containing the therapeutic compound in liposome-entrapped form, the surface-bound anti-ligand molecules, such as, avidin, and the PEG layer on the liposome surface are administered.

Example 1

Preparation of DSPE-PEG-Maleimide and Antibody Coupling to DSPE-PEG-Maleimide

Io PreRaration of the Mono 2-nitrobenzene-sulfonamide of PEG bis(amine) (Compound II)

A mixture of 1.7 g (0.5 mmole) of commercially available polyethylene glycol bis(amine) and 104 mg (0.55 mmole) of 2-nitrobenzene. . .

VII. Antibody Coupling to the Maleimide Grou'P of PEG

Coupling reactions were performed by adding antibody solution to the liposomes (final protein concentration = 0.5 mg/ml) in phosphate buffered saline and incubating the suspension overnight at ambient temperature with. . .

VIIIo Antibody Coupling to the Hydrazide Group of PEG

A 10 mg/ml solution of IgG was prepared in 100 mM sodium acetate, 70 mM NaCl pH 5 For 1 ml of protein. . . of 0.2 M sodium periodate was added. oxidation proceeded for 1 hour at room temperature. The periodate-treated protein was added to liposomes containing DSPE-PEG hydrazide and incubated overnight at 40C.

Liposomes were separated from free protein by chromatography on Sepharose CL-4B in TES-buffered saline, pH 7*4*

Example 2

Biodistribution of Antibody-Liposomes

The biodistribution and blood circulation lifetime of liposomes containing surface-bound antibodies was compared to that of liposomes lacking surface-bound antibodies. The antibody-liposomes were composed of HSPC:CH:PEG hydrazide, at a 2:1:0.1 molar ratio, and sheep IgG covalently linked to PEG chain. Liposomes lacking surface-bound antigens were liposomes composed of HSPC:CH:PEG at a 2:1:0.1 molar ratio and liposomes, composed of HSPC:CH:PEG hydrazide. The average diameter of the liposomes was between 110 and 120 nanometers. For biodistribution studies the liposomes contained 125I-tyraminylinulin in liposome-entrapped form (Example 2(I)). For blood circulation lifetime studies the liposomes contained OGallium in liposome-entrapped form, The antibody-liposomes were prepared as described in Example 1.VIII.

25

As shown in Table 1 the biodistribution of liposomes containing antibody covalently attached to the end of a PEG chain by a hydrazide group are very similar to those of liposomes containing 30 nonfunctionalized PEG chains. Liposome biodistribution was determined for the blood,

liver, spleen, lung, heart and carcass.

of either 0.2 ml phosphate-buffered saline (PBS) (untreated controls) or with 6 mg/kg of either free DOX, 6 mg/kg of DOX entrapped in HSPC:CH:PEG-DSPE liposomes (liposomal DOX), 6 mg/kg of DOX entrapped in HSPC:CH:PEG-DSPE liposomes containing attached antibody 174H.64 (mAb-liposomal DOX) or mAb-liposomes (11-39 Ag mAb) lacking DOX, all in 0*2 ml of sterile saline.

=> d kwic 6

L51 ANSWER 6 OF 11 .PCTFULL . COPYRIGHT 2005 Univentio on STN
ABEN Conjugates containing a substance with coagulant activity, such as recombinant Factor IX, non-antigenic polymers, such as poly(ethylene glycol), are disclosed. Also disclosed are methods of forming the novel conjugates of this invention.

ABFR . . . substance presentant une activite coagulante, tels que le facteur IX de recombinaison, et des polymeres non antigeniques tels que du poly(ethylene glycol); et procedes de preparation de ces nouveaux conjugues.

DETD . . . to a final concentration of 10 .mM and was allowed to sit on ice for 5 minutes, Excess periodate and sucrose were removed by desalting on a PD-10 column as described above. A 100 fold excess PEG-Hydrazide was added, and the reaction proceeded. . . . was added to a final concentration of 5 mM and the mixture was kept refrigerated overnight, Excess PEG and NaCNBH4 were removed by GPC-HPLC using a Showdex column equilibrated with 0,1 M sodium phosphate pH 7,5, SDS-PAGE of the purified material revealed a . . . 100 mM NaCl with 10 mg/ml glycine, The sample was aliquoted -and stored at either 40C, -700C or lyophilized, SDS-PAGE revealed an increased and broad molecular weight distribution but no sign of contaminating native protein, Specific activities were *determined in the presence of Factor IX def. . . .

SAMPLE SPECIFIC ACTIVITY (U/mg)

Native Factor IX 47

PEG-F, IX (40C) 128

PEG-F*IX (-700C) 146

PEG-F, IX (Lyoph) 115

The various embodiments of the present invention,, therefore, provide conjugates which retain significant levels of Factor IX activity while having less of a tendency to cause the formation of inhibitor antibodies.

=> d ibib 11

L51 ANSWER 11 OF 11 .PCTFULL . COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1986004145 PCTFULL ED 20020507
TITLE (ENGLISH): PROTEIN MODIFICATION WITH PEG
TITLE (FRENCH): MODIFICATION DE PROTEINES AVEC PEG
INVENTOR(S): TOMASI, Thomas, B.;
ANDERSON, William, L.
PATENT ASSIGNEE(S): UNIVERSITY OF NEW MEXICO

LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:
 DESIGNATED STATES
 W: DE GB JP
 APPLICATION INFO.: WO 1985-US2572 A 19851231
 PRIORITY INFO.: US 1984-687,811 19841231

=> d kwic 11

L51 ANSWER 11 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
 ABEN PEG-modified protein molecules characterized by reduced immunogenicity are prepared by covalent modification of the protein with PEG employing an active ester intermediate. Antibodies so modified exhibit decreased binding capacity for Fc cell surface receptors, are non-toxic and. . .

ABFR Des molecules de proteines modifiees par PEG (polyethylene glycol) caracterisees par une immunogenicite reduite sont preparees par modification covalente de la proteine avec PEG utilisant un intermediaire d'ester actif. Des anticorps ainsi modifies presentent une capacite de liaison diminuee pour des recepteurs en surface. . .

DETD PROTEIN MODIFICATION WITH PEG
 F i eld--of
 Diagnostic and therapeutic procedures of the type dependent upon immunoreaction of antibody with a target tissue are frequently hampered by both the immunogenicity of the reagent in clinical applications and binding to cell surface Fc receptors. Immune response to antibodies and other foreign proteins, characterized by both allergic phenomena and inactivation of the protein, must be countered by treatment of the protein to obviate stimulation of the host immune system, while retaining desirable protein biologic activity. In addition, it is desirable to increase antibody specificity by reduction or elimination of Fc binding to cell surface receptors.
 result was obtained in a related study J. T 1 nnol . hiad mm --l-le-t s., 327 (1983), wherein it was concluded that PEG-modification of Ig mediated with cyanuric chloride destroyed antibody activity.
 comprises a polyethylene glycol-protein derivative, and a method for preparing the derivative in excellent yields comprising covalently modifying the protein with polyethylene glycol (PEG) employing an active ester intermediate. Derivatized antibodies are characterized by retained antigen binding activity, low binding capacity for cell surface Fc receptors reduced immunogenicity, good storage stability, and non-toxicity and are. . . such as tumor imaging, chemotherapy, radiotherapy, and immunohistochemical procedures. It is contemplated that a broad range of diagnostic and therapeutic proteins including monoclonal antibodies and enzymes, is modifiable by the process of the invention to provide

modified proteins having reduced immunogenicity and low non-specific biological.

Different symbols depict experiments performed on different days with different samples of PEG-modified antibody

An affinity purified rabbit anti-mouse immunoglobulin reagent was modified with FITC to an F/P ratio of 3.7 Qj) A fraction TPIPTOM Qz TRE

According to the invention, immunogenicity of foreign protein, especially antibody is reduced or eliminated by covalent

modification of the protein with polyethylene glycol (PEG), employing a PEG active ester intermediate. In contrast to known

prior art modifications, PEG modification of antibodies according

to the process of the invention provides a derivative which retains avidity for antigen, while exhibiting reduced immunogenicity. A particular advantage . . . reduction in non-specific binding occurs which

is believed to be attributable to inactivation of the Fc portion of the antibody molecule. The process thus substantially eliminates binding of the antibody to cell surface Fc receptors and promotes

antibody concentration targeted tissue in applications such as tumor imaging and immunohistochemical techniques.

Particular PEG polymers useful in the process of the invention comprise substituted or unsubstituted PEG polymers having molecular weights of from about 1000 to 5000 which are themselves poor immunogens, and which can be coupled to protein using . . . biologically active and substantially non-toxic and non-immunogenic. Monomethoxypolyethylene glycol (mPEG) satisfies these criteria, and is an especially suitable modifier, particularly for antibody. Covalent mPEG modification of antibody molecule, using the present active ester approach is accomplished with full retention of binding activity, and yields very predictable and reproducible modifications.

While the process is particularly useful in reducing the immunogenicity of heterologous species proteins the process is also applicable to homologous species proteins. Antibodies are proteins of particular interest, as by the process of the invention, the specificity and avidity of the antibody molecules is retained, while non-specific binding of antibody molecules to cellular Fc receptor and rapid clearance of the antibody from the circulation is obviated. Drugs, toxins, fluorescents, radionuclides, or other active moieties may readily be attached to the modified antibody molecule via the PEG substituent according to principles

understood by those skilled in the art for delivery to selected tissue, especially to tumor tissue for diagnosis or therapy, owing to the decreased non-specific activity of complexes comprising active moieties conjugated with PEG-modified antibody or other protein, premature dissociation of the complex is avoided and highly selective delivery is achieved.

brief, antisera was applied to the affinity column and the column was washed

with 0.5 U sodium thiocyanate and the resulting antibody was simultaneously desalting and concentrated using a Micro Pro di Con apparatus, (Bio 11oleculare Dynaraicso Beavertonw OR), The purified antibody was stored sterile at 4 degrees, .-e.assurement: o.f Anti-Cgnaalbumin Activit Nnt'gen binding activity of the affinity purified and chemical-Ly modified antibodies was determined by evaluating their ability to competitively inhibit the binding of a rabbit anti-conalbuimin-alkaline phosphatase conjugate to conalbumin-coated micAroelisa plates (Vanguard, Neptune, NJ). The enzyme linked antibody for this assay was prepared by a modification of the method described by Avermeas (Ii-timuno. Chem.]: 43j, 1969) and to assure. . . conalbumin to 10 ug/ml in 0.05 U NaHCO₃ r pH 9.6 and incubating for 18 hours at room temperature, Equal volumes of antibody and enzyme conjugate, at the proper dilution, were then incubated in the antigen coated plates with Characteriza-tio.ja-af. Mo4iflief.-Antibod Three different measurements were used to characterize the modified antibody. Protein concentration was determined both by optical density measurements at 280 nm, assuming an E % 280nm = 14 Qlatho.ds.-Immuna.l. Immunocbem.2: 343, . . . , 1 948) Protein amino groups were determined by TNBS titrations as described by Habeed (Ana lyt... Bioc .,hp.m.- 1,4: 323#, 1966) The extent of PEG modification was also evaluated by measuring an increase in protein size. For this measurement protein size was evaluated using a 06% discontinuous. . .

Dete-rrmination-of- immunageni-ai= Immunogenicity of rabbit antibody and its PEG -modified derivatives were determined by measuring the antibody response of Swiss mice to an intraperitoneal injection of 50 gg of the antigen (rabbit antibody) in PBS. The mouse antibody response was determined using a two step enzyme linked assay, In brieft several two-fold dilutions of mouse sera were incubated on a rabbit. . .

The effect of mPEG modifications, using cyanuric chloride and active ester coupling procedures on antibody activity is reported in Table I and II. It is evident from these results that even at low modifications there is a significant decrease in antibody binding activity with cyanuric chloride.

Experiments varying the rate and form of activated PEG along with experiments varying the reaction time and temperature did not significantly improve the recovery of active antibody. In contrastf the use of active ester to modify antibody with PEG results in no detectable loss in antibody titer or antibody activity.

TABLE I
Antigen &jnding >jyity.of -Rat' alhimin
Mad if i ad -with ag using -the,];Xantiric Chlogigle. Procrdure
& Lysine
liodification mg Antibody/mg Protein % Loss of Ab Activity
1*00 0
0050 50
0*15 35
0*06 94
TABLE II
Acylyty, __of. Rabbit

Anti-CQ Modi-f i-ed. with
ha, ra&=9 ;Ler- of
% Lysine
Modification mg Antibody/mg Protein % Loss of Ab Activity
1 0 0 0
1*0 0
1*0 0
1*0 0
100 0
1*0 0
at ion, o

EXAMPTA.-I-n-, Effectiy. ansa Qf

I..--w th_mPZQ. a lo-the-,

To verify that antibody was significantly modified by this procedure, all mPEG-modified antibody preparations were analyzed by SDS gel electrophoresis. An example of one series of derivatives is shown in FIG. 1e. Results from this experiment clearly show that most or all molecules in the population are modified and that the apparent molecular weight increases greatly

following the modification. II-. should be noted however that the -modified antibodies tested are a distribution of molecules

each containing different number of PEG molecules per antibody.

B. The hyperresponsiveness induced by some of the mPEG-modified rabbit antibodies in A, gap-ra, was investigated by evaluating the adjuvant properties of PEG. Swiss mice were immunized with 50 mg of rabbit immunoglobulin in the presence of varying PEG concentrations up to 1 mg/ml PEG and the antibody response determined fifteen days later. In this experiment the PEG was not covalently attached to the rabbit protein.

appear to have

an upper limit to the cellular fluorescence intensity whereas cells detected by the reagent that was not mPEG-modified show an increased fluorescence intensity (FIG. 7B)o

Co It was demonstrated that the mPEG-modified reagent binds to cell surface immunoglobulin whereas the non mPEG-modified reagent exhibits. . . ritimunoglobulin was used to competitively inhibit the binding of both reagents to mouse splenocytes. The results of this experiment, shown in FIG. 8,

clearly demonstrate that the binding of the classical fluoresceinated reagent (not mPEG-modified) could not be completely, inhibited by antigen whereas binding of. . .

PEG-modified antibodies according to the invention exhibit

markedly reduced immunogenicity, low specific binding capacity for cell surface Fc receptors, and retention of antigen-binding activity. mPEG modification of antibodies also essentially eliminates Fc receptor binding. Covalent modification of more than 15% of amino groups of rabbit anti-conalbumin antibody with mPEG completely prevented immune complexes prepared with this antibody from binding to the Fc receptor on the murine rLiacrophage cell line P388,D1. Similar sensitivities are observed for mPEG-modified fluorescein labelled antibodies since mPEG modification does not quench fluorescein fluorescence. A fluorescein WO 86/04145 PCT/US85/02572

=> d his

(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)

FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
E "PEG"/CN 25

L1 1 S E3

FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005

L2 185 S L1
L3 9685 S PEG
L4 2487 S POLY () ETHYLENE () GLYCOL
L5 52 S METHOXPOLY () ETHYLENE GLYCOL
L6 10866 S L5 OR L4 OR L3
L7 694206 S ANTIBOD?
L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L9 1041 S L8 AND L6
L10 129 S L9 AND L7
L11 7 S ANTI-PEG
L12 2 S L11 AND L8
L13 3 S L11 NOT PY>1999
L14 97 S L10 NOT PY>1999
L15 90 S L14 NOT PY>1998
L16 1898836 S INCREASE? OR ACCELERAT?
L17 .24 S L16 AND L15
L18 51664 S L16 (S) L8
L19 7 S L18 AND L17

FILE 'CAPLUS' ENTERED AT 08:17:28 ON 23 AUG 2005

L20 33476 S PEG
L21 12996 S POLY () ETHYLENE () GLYCOL
L22 144 S METHOXPOLY () ETHYLENE GLYCOL
L23 41717 S L22 OR L21 OR L20
L24 440322 S ANTIBOD?
L25 1304988 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L26 1459976 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L27 3736368 S INCREASE? OR ACCELERAT?
L28 99738 S L26 (S) L27
L29 1750 S L24 AND L28
L30 16 S L29 AND L23
L31 9 S ANTI-PEG
L32 3 S L31 NOT PY>1999
L33 6 S L30 NOT PY>1998

FILE 'PCTFULL' ENTERED AT 08:22:07 ON 23 AUG 2005

L34 35377 S PEG
L35 5321 S POLY () ETHYLENE () GLYCOL
L36 76 S METHOXPOLY () ETHYLENE GLYCOL
L37 80487 S ANTIBOD?
L38 492783 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L39 496097 S INCREASE? OR ACCELERAT?
L40 83462 S L38 (S) L39
L41 7 S ANTI-PEG
L42 5 S L41 AND L40
L43 38102 S L34 OR L35 OR L36
L44 3934 S L43 (S) L37
L45 1413 S L44 AND L40
L46 1018 S L44 (P) L40
L47 3 S ANTI () (POLYETHYLENE GLYCOL)
L48 282 S L46 NOT PY>1999
L49 930 S L43/AB
L50 12 S L49 AND L48
L51 11 S L50 NOT PY>1998

=> file dissab
COST IN U.S. DOLLARS

SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	56.84	135.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-1.46

FILE 'DISSABS' ENTERED AT 08:36:44 ON 23 AUG 2005
 COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE COVERS 1861 TO 30 JUL 2005 (20050730/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

```
=> s anti-peg
  25082 ANTI
    9 ANTIS
  25087 ANTI
    (ANTI OR ANTIS)
  1251 PEG
  154 PEGS
  1334 PEG
    (PEG OR PEGS)
L52      0 ANTI-PEG
    (ANTI(W) PEG)
```

```
=> s anti () (polyethylene glycol)
  25082 ANTI
    9 ANTIS
  25087 ANTI
    (ANTI OR ANTIS)
  3287 POLYETHYLENE
  146 POLYETHYLENES
  3344 POLYETHYLENE
    (POLYETHYLENE OR POLYETHYLENES)
  2420 GLYCOL
  177 GLYCOLS
  2537 GLYCOL
    (GLYCOL OR GLYCOLS)
  930 POLYETHYLENE GLYCOL
    (POLYETHYLENE(W) GLYCOL)
L53      0 ANTI (W) (POLYETHYLENE GLYCOL)
```

```
=> d his
(FILE 'HOME' ENTERED AT 08:05:57 ON 23 AUG 2005)
```

```
FILE 'REGISTRY' ENTERED AT 08:06:15 ON 23 AUG 2005
  E "PEG"/CN 25
L1      1 S E3
```

```
FILE 'MEDLINE' ENTERED AT 08:07:04 ON 23 AUG 2005
L2      185 S L1
L3      9685 S PEG
L4      2487 S POLY () ETHYLENE () GLYCOL
L5      52 S METHOXYPOLY () ETHYLENE GLYCOL
L6      10866 S L5 OR L4 OR L3
L7      694206 S ANTIBOD?
```

L8 538410 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L9 1041 S L8 AND L6
L10 129 S L9 AND L7
L11 7 S ANTI-PEG
L12 2 S L11 AND L8
L13 3 S L11 NOT PY>1999
L14 97 S L10 NOT PY>1999
L15 90 S L14 NOT PY>1998
L16 1898836 S INCREASE? OR ACCELERAT?
L17 24 S L16 AND L15
L18 51664 S L16 (S) L8
L19 7 S L18 AND L17

FILE 'CAPLUS' ENTERED AT 08:17:28 ON 23 AUG 2005
L20 33476 S PEG
L21 12996 S POLY () ETHYLENE () GLYCOL
L22 144 S METHOXYPOLY () ETHYLENE GLYCOL
L23 41717 S L22 OR L21 OR L20
L24 440322 S ANTIBOD?
L25 1304988 S CLEARANCE OR CLEAR OR EXCRET? OR REMOVED OR REMOVAL
L26 1459976 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L27 3736368 S INCREASE? OR ACCELERAT?
L28 99738 S L26 (S) L27
L29 1750 S L24 AND L28
L30 16 S L29 AND L23
L31 9 S ANTI-PEG
L32 3 S L31 NOT PY>1999
L33 6 S L30 NOT PY>1998

FILE 'PCTFULL' ENTERED AT 08:22:07 ON 23 AUG 2005
L34 35377 S PEG
L35 5321 S POLY () ETHYLENE () GLYCOL
L36 76 S METHOXYPOLY () ETHYLENE GLYCOL
L37 80487 S ANTIBOD?
L38 492783 S CLEARANCE OR CLEAR? OR EXCRET? OR REMOVED OR REMOVAL
L39 496097 S INCREASE? OR ACCELERAT?
L40 83462 S L38 (S) L39
L41 7 S ANTI-PEG
L42 5 S L41 AND L40
L43 38102 S L34 OR L35 OR L36
L44 3934 S L43 (S) L37
L45 1413 S L44 AND L40
L46 1018 S L44 (P) L40
L47 3 S ANTI () (POLYETHYLENE GLYCOL)
L48 282 S L46 NOT PY>1999
L49 930 S L43/AB
L50 12 S L49 AND L48
L51 11 S L50 NOT PY>1998

FILE 'DISSABS' ENTERED AT 08:36:44 ON 23 AUG 2005
L52 0 S ANTI-PEG
L53 0 S ANTI () (POLYETHYLENE GLYCOL)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.41	136.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.46

STN INTERNATIONAL LOGOFF AT 08:37:23 ON 23 AUG 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * * * * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
	2	"Ask CAS" for self-help around the clock
NEWS	3	CASREACT(R) - Over 10 million reactions available
NEWS	4	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	5	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	6	CA/CAplus to be enhanced with updated IPC codes
NEWS	7	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	8	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	9	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	10	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC.
NEWS	11	Pre-1988 INPI data added to MARPAT
NEWS	12	IPC 8 in the WPI family of databases including WPIFV
NEWS	13	Saved answer limit increased
NEWS	14	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	15	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	16	Status of current WO (PCT) information on STN
NEWS	17	The IPC thesaurus added to additional patent databases on STN
NEWS	18	Updates in EPFULL; IPC 8 enhancements added
NEWS	19	New STN AnaVist pricing effective March 1, 2006
NEWS	20	MEDLINE/LMEDLINE reload improves functionality
NEWS	21	TOXCENTER reloaded with enhancements
NEWS	22	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	23	INSPEC reloaded and enhanced
NEWS	24	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS EXPRESS		FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS		STN Operating Hours Plus Help Desk Availability